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CHAPTER - 1 
INTRODUCTION 
The main goal of pharmaceutical formulation is to achieve better therapeutic 
activity in the shortest possible time by using smallest quantity of drug administered 
by the most suitable route
1
. 
Drugs can be administered through different routes; however, of all the 
routes of administration, oral route of administration is most convenient for 
administering drugs for systemic effect because of ease of administration and dosage 
adjustments
2
. Parenteral route is not routinely used because of difficulty in self-
administration and hence hospitalization may be required. Topical route is recently 
developed and is employed for only few drugs like nitroglycerine, scopolamine, for 
systemic effect. Topical route has limitations in its ability to allow effective drug 
absorption for systemic drug action. Parenteral administration is employed in case of 
emergency and in which the subject is comatose or cannot swallow. Nevertheless it 
is possible that at least 90% of all drugs used to produce systemic effect are 
administered by oral route
3
. 
Oral route of drug administration has wide acceptable and of the drugs 
administered orally in solid dosage forms represents the preferred class of products. 
The reasons are follows: ―tablets and capsules represent unit dosage forms in which 
one usual dose of drug has been accurately placed‖. 
Solid dosage forms of tablets and capsules are more commonly employed, 
the tablets have advantages than capsules in that they are tamper resistant and any 
adulterant of the tablet after its manufacture is almost certain to be observed. The 
adulteration can be easily found if it is done in either liquid form or solid form since 
deformation takes place, if it is done in liquid form and powders cannot be added to 
the tablet if once they are formed. The major disadvantage of capsules over tablet is 
their higher cost. The capsules either hard capsule or soft capsule they are 
susceptible to breakage if they are not stored properly. 
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1.1 TABLETS: 
 Tablets may be defined as solid pharmaceutical dosage forms containing 
drug substances with or without suitable diluents and prepared either by 
compression or molding methods. In European pharmacopoeia tablets are also 
defined as ―Solid preparations each containing a single dose of one or more active 
ingredients and obtained by compressing uniform volume of particles‖. They have 
been in widespread use since the latter part of the 19
th 
century and their popularity 
continues
1, 2
.  
 Tablets remain popular as a dosage form because of the advantages, afforded 
both to the manufacturer [e.g.: simplicity & economy of preparation, stability and 
convenience in packing, shipping, and dispensing] and the patient [e.g.: accuracy of 
dosage, compactness, post ability, blandness of taste and ease of administration]. 
 Although tablets are more frequently discoid in shape, they also may be 
round, oval, oblong, cylindrical or triangular. They may differ greatly in size and 
weight depending on the amount of drug substance present and the intended method 
of administration. 
a) Properties of Tablets
1
: 
The attributes of an acceptable tablet are as follows: 
 The tablet must be sufficiently strong and resistance to shock and 
abrasion and to withstand handling during manufacturing, packing, 
shipping, and use. Hardness and friability tests measure this property. 
 Tablet must be uniform in weight and in drug content of the individual 
tablet. This is measured by the weight variation and content uniformity 
tests. 
 The drug content of the tablet must be bioavailability. This property is 
measured by the dissolution test. Accurate bioavailability can be obtained 
from the drug levels of the drug after its administration. 
 Tablets must be elegant in appearance and must have characteristic 
shape, color, and other markings necessary to identify the product. 
 Tablets must retain all these functional attributes, which include drug 
stability and efficacy. 
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b) Advantages of Tablets
2
: 
 They are easy to administer. 
 They are a unit dosage form, and they offer the greater capabilities of all 
oral dosage forms for the greatest dose precision and the least content 
variability. 
 Their cost is lowest of all oral dosage forms. 
 They are the lightest and most compact of all oral dosage forms. 
 Product identification is potentially the simplest and cheapest, requiring 
no additional processing steps when employing an embossed or 
monogrammed punch face. 
 They are in general the easiest and cheapest to package and ship of all 
oral dosage forms. 
 They may provide the greatest ease of swallowing with the least tendency 
for ―hang-up‖ above the stomach. Especially when coated, provided that 
tablet disintegration is not excessively rapid. 
 They lend themselves to certain special release profile products, such as 
enteric or delayed release products. 
 They are better suited to large-scale production than other unit oral 
forms. 
 They have the best-combined properties of chemical, mechanical and 
microbiological stability of all the oral forms.  
 One of the major advantages of tablet over capsules is that the tablet is 
essentially ―tamperproof dosage form‖. 
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c) Disadvantages of Tablets
2
: 
 Some drugs resist compression into dense compacts, owing to their 
amorphous nature or flocculent, low-density character. 
 Drugs with poor wetting, slow dissolution properties, intermediate to 
large dosages, optimum absorption high in the gastrointestinal tract, or 
any combination of these features may be difficult or impossible to 
formulate and manufacture as a tablet that will still provide adequate or 
full drug bioavailability. 
 Bitter tasting drugs, drugs with objectionable odor or drugs that the 
sensitive to oxygen or atmosphere moisture may require encapsulation or 
a special type of coating with may increase the most of the finished 
tablets.   
d) Types of Tablets
1
: 
 Tablets are classified according to their route of administration or function. 
The following are the 5 main classification groups: 
 
 Tablets ingested orally  
 Compressed tablets 
 Multiple compressed tablets 
 Multilayered tablets 
 Sustained action tablets 
 Enteric coated tablets 
 Sugar coated tablets 
 Film coated tablets 
 Chewable tablets 
 Tablets used in the oral cavity 
 Buccal tablets 
 Sublingual tablets 
 Lozenge tablets and torches   
 Dental cones 
 Tablets administered by other routes 
 Implantation tablets 
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 Vaginal tablets 
 Tablets used to prepare solutions  
 Effervescent tablets 
 Molded tablets or tablet triturates (TT) 
 Dispensing tablets (DT) 
 Hypodermic tablets (HT) 
1.2 TABLET MANUFACTURING
4
: 
Tablets are compressed powders and their manufacturing is a complex, 
multistep process. The ultimate aim is to easily disperse in gastrointestinal fluid and 
in complete absorption of API and at the same time, offer stability to the 
formulation. 
The tablet manufacturing process can be broadly classified as: 
1) Granulation method 
a. Wet granulation method 
b. Dry granulation method 
2) Direct compression method 
Oral dosage forms mainly solid dosage forms are more popular than other 
dosage forms but suffer from problems like solubility, absorption Viz. 
bioavailability, therefore patient compliance. Immediate release/conventional dosage 
form is one of the approach to achieve the above goal. As dissolution rate is related 
to absorption and bioavailability, increased dissolution rate will increase absorption 
to give faster onset of action.   
The enhancement of oral bioavailability of poorly water soluble drugs 
remains one of the challenging aspects of drug development together with the 
permeability. The solubility behavior of a drug is key determinate of its oral 
bioavailability. There have always been certain drugs for which solubility has 
presented a challenge to the development of a suitable formulation for oral 
administration. The most important property of a dosage form is its ability to deliver 
the active ingredient to its site of action in an amount sufficient to elicit the desired 
pharmacological response. This property of the dosage form has been referred to as 
its physiological availability. 
Bioavailability is defined more precisely as the rate and extent of absorption 
of a drug from its dosage form into the systemic circulation. Accordingly the 
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absorption of an intravenously administered drug is instantaneous and complete. 
However, for reasons of convenience and stability, most drugs are administered 
orally offer first being formulated into dosage forms usually tablets and capsules. 
The rate and extent of absorption from such dosage forms is usually not precisely 
known as it is affected by a number of factors related to the drug, dosage form and 
patient. 
 
Fig No. 1: Dissolution and Absorption of Drugs from Solid Dosage Forms
3
 
When a drug is administered orally in a solid dosage form such as tablet, 
capsule it must be released from the dosage form and dissolved in the gastro 
intestinal fluid before it can be absorbed
3
. The bioavailability of many poorly water 
soluble drugs is limited by their dissolution rates, which are in turn controlled by the 
surface area that they present for dissolution
6
. Two consecutive transport processes 
can be identified to describe the oral absorption of drugs from solid dosage forms. 
1. Dissolution of the drug in vivo to produce a solution  
2. Transport of the dissolved drug across the gastrointestinal membrane. 
Each process can be characterized by a rate constant. If the rate of 
dissolution of the drug is significantly slower than the rate of absorption, the 
dissolution of the drug becomes the rate-limiting step in the absorption process, and 
the particle size of the drug is of greater importance in the transport from the 
gastrointestinal (GI) tract to the site of action Most drugs are passively absorbed and 
their rates of absorption are dependent upon the concentration gradients in each 
case; by increasing the dissolution rate in GI tract, the absorption rate increases, so 
long as the dissolution rate is still the limiting step
5
. This commonly occurs for 
drugs with limited water solubility. 
Solid dosage form 
Disintegration 
Granules 
Fine particles 
Dissolution 
Dissolution 
 
Dissolution 
Drug in solution 
  at the  
Absorption site 
GI Barrier 
Drug in 
Blood, other 
fluids & 
Tissues 
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Fig No. 2: The Two Rate limiting Steps in the Absorption of Drugs from orally 
administered formulations
3
 
1.3. THEORIES OF DISSOLUTION: 
Dissolution rate may be defined as the amount of drug substance that is 
dissolved per unit time under standardized conditions of liquid-solid interface, 
temperature and solvent composition. Dissolution can be considered a specific type 
of heterogeneous reaction in which a mass transfer results a net effect between the 
escape and deposition of solute molecules at a solid surface. The most common 
theory for dissolution, the film theory, also known as the diffusion layer model 
accepts the assumption that dissolution belongs to a type of heterogeneous reaction 
where the rate is determined by the transport process
3
.  
The following is the brief interpretation of this as well as some other 
important dissolution theories. 
a. Noyes-Whitney and Nernst-Brunner Equations: 
Noyes and Whitney in 1897
6
 stated that the rate at which a solid substance 
dissolved in its own solution is proportional to the difference between the 
concentration of that solution and the concentration of the saturated solution. 
Mathematically it can be expressed as
 
( )s b
dc
K C C
dt
   
Where: dc = the dissolution rate 
              K = proportionality constant   
             Cs = the solubility of the solute 
             Cb = the concentration at any time, t 
The Noyes - Whitney equation can be explained as: 
Solid 
dosage 
form 
Disintegration Solid drug 
particles 
Dissolution 
RLS for 
lipophilic 
drugs 
Drug in 
solution at the 
absorption site 
Drug in blood 
circulation 
RLS for 
hydrophilic 
drugs 
Permeation 
across the 
biological 
membrane 
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A thin layer of saturated solution is formed at the surface of the solid and the rate of 
dissolution is governed by the rate of diffusion from this layer to the bulk of the solution. 
There is negligible change in the surface area with time during dissolutions. 
Noyes-Whitney, Brunner
7
 and Tolloczko
8
 revised the equation assuming, that 
under well-defined conditions of temperature and agitation, the dissolution rate is 
proportional to the surface area ‗S', giving. 
1( )s b
dc
K C C
dt
   
Where: K1 = called the intrinsic dissolution rate constant.  
Applying Fick's law of diffusion to Nernst
9
 and Brunner
10 
equation 
( )s b
dc DS
C C
dt hv
 
 
Where: D = the diffusion coefficient of the solute. 
              h = the thickness of the diffusion layers. 
             V = the volume of the dissolution medium. 
  S= surface area 
This has been referred to as film theory of Nernst Brunner, which applies to some 
situations.  
b. Cube root law: 
Hixson and Crowell
12
 introduced the concept of changing surface area during 
dissolution and derived the "Cube root law" given by. 
1/3
1/3 1/3
1
2
( ) ( )
6
s
O
Dc tNP
W W
hp
 
   
 
 
Where: W0 = the initial weight of solid. 
              W1 = the weight of solid at time, t. 
              N   = the number of particles. 
              P    = the density of the solid.  
This equation is based on a number of assumptions:  
1. Dissolution takes place normal to the surface of the dissolving solid particles. 
2. No stagnation of liquid occurs in any region. 
3. The same effect of agitation is observed on all areas of the solid surface.  
4. Solid particles remain intact during the dissolution process and  
5. The stagnant or diffusion layer thickness is independent of the particle diameter 
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1.4. FACTORS INFLUENCING DRUG ABSORPTION FROM ITS DOSAGE 
FORM
3,5
: 
    
 
1. Pharmaceutical factors: Include factors relating to the physicochemical 
properties of the drug and dosage form characteristic and pharmaceutical 
ingredients. 
a) Physicochemical properties of the drug substances 
 Drug solubility and dissolution rate  
 Particle size and effective surface area  
 Polymorph and amorphism 
 Pseudo polymorphism 
 Salt form of the drug 
 Lipophilicity of the drug 
 Pka of the drug and pH  
 Drug stability 
b)  Dosage Form Characteristics 
 Disintegration time 
 Dissolution time 
 Manufacturing variables 
 Pharmaceutical ingredients (excipients / adjuvants) 
 Nature and type of dosage form 
 Product and storage conditions 
2. Patient Related Factors: Include factors relating to the anatomical, 
physiological and pathological characteristics of the patient 
 Age 
 Gastric emptying time 
 Intestinal transit time 
 Gastro intestinal pH 
 Disease states 
 Blood flow through the GIT 
 Gastrointestinal contents 
 Pre-systemic metabolism 
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1.5. METHODS AVAILABLE TO ENHANCE THE DISSOLUTION RATE: 
As far as the definition of bioavailability is concerned, a drug with poor 
bioavailability is the one with, poor aqueous solubility and / or slow dissolution rate 
in the biologic fluids, poor stability of the dissolved drug at the physiological p
H
, 
inadequate partition coefficient and thus poor permeation through the bio-membrane 
and extensive pre-systemic metabolism. 
  The three major approaches in overcoming the bioavailability problems due 
to such causes are, 
 The Pharmaceutical Approach 
 The Pharmacokinetic Approach 
 The Biological Approach 
1. The Pharmaceutical Approach: This involves modification of formulation, 
manufacturing process or the physicochemical properties of the drug without 
changing the chemical structure. 
2. The Pharmacokinetic Approach: In which the pharmacokinetics of the 
drug is altered by modifying its chemical structure. 
3. The Biological Approach: Where by the route of administration may be 
changed such as changing from oral to parentral route. 
Methods available to enhance the Dissolution Rate of poorly soluble drugs                                                    
Method Examples of drug 
Methods which increases solubility of the drug 
a. Buffering the pH of the environment 
b. Use of salts of weak acids and bases 
c. Use of solvates and hydrates 
 
d. Use  of  selected polymorphic forms 
Complexation 
e. Pro drug approach 
f. Use of surfactants 
 
 
Buffered Aspirin tablets
 
 
Sodium, potassium and Calcium salts of P-amino 
salicylic acid 
Ampicillin hydrate, solvated forms of succinyl 
sulfathiazole,Novobiocin, 
Chloramphenicol palmitate 
 
Benzocaine – Caffeine 
complex
 
Prodrugs of Ampicillin in Pirampicillin      
Hydrocortisone - Tween 80 
Tolbutamide - Tween 20
 
Methods which increase the surface area of the drug. 
a. Micronization 
(Particle size reduction to increase the 
surface area) 
b. Use of surfactants 
(to increase effective surface area by 
facilitating proper wetting) 
c. Solvent deposition 
(Deposition of poorly soluble drugs on inert 
materials) 
d. Solid Dispersions 
(Dispersion of poorly soluble drug in a 
solid matrix of water soluble carrier). 
Griseofulvin, Digoxin, Phenacetin 
 
 
Phenacetin 
 
 
Oxyphenbutazone, Predinisolone, 
 
Indomethacin 
 
Griseofulvin – PVP, Reserpine – PVP 
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DISEASE PROFILE: 
1.6 (I) Community Acquired Pneumonia  
Definition  
Community acquired pneumonia (CAP) refers to a serious infection or 
inflammation of the lungs that is generally acquired outside of a hospital or long 
term care facility. When this infection is acquired, the air sacs in your lungs fill 
with pus or other liquid, making it difficult for oxygen to penetrate through your 
lungs to reach your bloodstream. If CAP is not treated properly with antibiotics 
or spreads throughout your body, it can result in death, especially in the elderly 
or in people with weakened immune systems 
Causes 
Community acquired pneumonia is spread by close person-to-person contact—
usually when an infected person coughs or sneezes on another person. CAP can 
be caused by several different organisms, including bacteria, viruses, and fungi. 
The most common organism responsible for CAP is the bacterium known as 
Streptococcus pneumoniae. Although several "bugs" or organisms have been 
confirmed to be causes of CAP, about 30% to 50% of pneumonia cases are 
reported to have an unknown cause—meaning the exact "bug" responsible for 
the infection is unknown or is not identified via laboratory testing. 
About CAP 
In the United States, CAP (combined with influenza or "the flu") is the eighth 
leading cause of death and the number one cause of death from infectious 
diseases. It is estimated that approximately 5.6 million cases of CAP occur 
annually and of these 1.1 million require hospitalization. Anyone can be 
susceptible to CAP, but it more commonly occurs in very young (less than 2 
years of age) or elderly people. CAP is also more common in people who smoke 
or have other severe illnesses, such as chronic obstructive pulmonary disease 
(COPD), alcoholism, cancer, organ transplants, kidney disease, and immune 
system disorders.  
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Risk Factors 
Risk factors are characteristics that may increase the chance for developing a 
condition. The more risk factors present, the more likely you are to develop the 
condition. You are at an increased risk for developing CAP if you:  
 Are 65 years or older  
 Have other medical conditions or a combination of conditions such as:  
1.  Chronic obstructive lung disease (COPD) or other chronic lung disorders  
2.  Diabetes mellitus  
3.  Chronic kidney disease  
4.  Heart failure  
5.  Coronary artery disease  
6.  Cancer  
7.  Chronic liver disease  
8.  Cystic fibrosis  
 Are a smoker  
 Are exposed to certain chemicals or pollutants such as those used for agriculture, 
construction, or industrial chemicals. Exposure to these pollutants can sometimes 
cause damage to the lungs and contribute to lung inflammation—thus leaving the 
lungs more susceptible to infection.  
 Suffer from alcoholism and have a weakened immune system  
 Symptoms 
CAP sometimes presents after a cold, the flu, or any condition that damages the 
defenses of the airways that would allow bacteria to infect them. The symptoms 
of CAP can vary and generally overlap with other symptoms of the common 
cold or flu. This variability makes it sometimes difficult to recognize pneumonia. 
Many people attribute it to a cold that just won‘t go away. However, CAP can be 
life-threatening if it is not properly treated.  
``Some symptoms that you may notice with community acquired pneumonia 
include, but are not limited to:  
 Shaking and chills ,Fever  
 A cough that produces sputum—usually rust colored (or burnt orange)  
 Shortness of breath and Chest pain worsened by deep breathing or 
coughing  and Night sweats  
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Treatment  
Treatment for CAP varies according to the organism responsible for the 
infection. If the cause is bacterial, then the goal of treatment is to cure the 
infection with antibiotics, which can typically be taken orally at home if the 
infection is not severe. If the infection is severe, if the person is having difficulty 
breathing, or has other chronic medical conditions, then intravenous (IV—
injected into a vein) antibiotics may be needed and are usually administered in a 
hospital. If the infection is viral, the goal is to alleviate any signs and symptoms 
of the infection through supportive care (such as fever reduction with 
acetaminophen) since there is no cure for a virus.  
Because several treatment guidelines are available, the specific drug(s) that your 
doctor may use to treat your CAP may vary. Clinical expertise/preference and 
antibiotic drug resistance in a particular area are two factors that may affect a 
doctor‘s drug of choice for treating CAP.  
At the initial visit to the doctor, he or she will question you about your past 
medical history and perform a physical examination. It may be necessary to 
perform a chest X-ray. Next, your doctor will determine how much your 
infection places your life at risk. Your doctor may need to send samples of your 
sputum, blood or urine to the laboratory to confirm your CAP diagnosis. Doctors 
will usually prescribe "empiric therapy"—prescribing therapy based on the 
suspected cause (bacteria, virus, or fungi) using clinical or practical expertise—
because the specific organism responsible for the infection is usually not yet 
identified before treatment is started. After the organism is identified, therapy 
can be tailored to treat that specific organism. The following chart describes the 
guidelines from the Infectious Diseases Society of America and American 
Thoracic Society for patients that don't need to be hospitalized.  
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1.7 (ii) Toxoplasmosis 
Definition 
Toxoplasmosis is an infectious disease caused by the one-celled protozoan 
parasite Toxoplasma gondii. Although most individuals do not experience any 
symptoms, the disease can be very serious, and even fatal, in individuals with 
weakened immune systems. 
 Description 
Toxoplasmosis is caused by a one-celled protozoan parasite known as 
Toxoplasma gondii. Cats, the primary carriers of the organism, become infected 
by eating rodents and birds infected with the organism. Once ingested, the 
organism reproduces in the intestines of cats, producing millions of eggs known 
as oocysts, which are excreted in cat feces daily for approximately two weeks. In 
the United States, it is estimated that approximately 30% of cats have been 
infected by T. gondii. Oocysts are not capable of producing infection until 
approximately 24 hours after being excreted, but they remain infective in water 
or moist soil for approximately one year. When cattle, sheep, or other livestock 
forage through areas with contaminated cat feces, these animals become carriers 
of the disease. Fruits and vegetables can also become contaminated when 
irrigated with untreated water that has been contaminated with cat feces. In 
humans and other animals, the organisms produce thick-walled, dormant 
structures called cysts in the muscle and other tissues of the body. 
Most humans contract toxoplasmosis by eating cyst-contaminated raw or 
undercooked meat, vegetables, or milk products. Humans can also become 
infected when they come into contact with the T. gondii eggs while cleaning a 
cat's litterbox, gardening, or playing in a sand-box, for instance. Once infected, 
an individual is immune to reinfection. The incubation period or period between 
infection and the start of the disease ranges from several days to months. 
Anyone can be infected by T. gondii, but usually only those individuals with 
weakened immune systems (immunocompromised) develop symptoms of the 
disease. For them, toxoplasmosis can be severe, debilitating, and fatal. 
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Immunocompromised individuals at risk include those with AIDS, cancer, or 
other chronic illnesses. 
There is no person-to-person transmission, except from an infected mother to her 
child in the womb. Approximately six out of 1,000 women contract 
toxoplasmosis during pregnancy. Nearly half of these maternal infections are 
passed on to the fetus. Known as congenital toxoplasmosis, this form of the 
disease is acquired at birth by approximately 3,300 infants in the United States 
every year. The risk of fetal infection is estimated to be between one in 1,000 to 
one in 10,000. In children born with toxoplasmosis, symptoms may be severe 
and quickly fatal, or may not appear until several months or even years after 
birth. 
Causes and symptoms 
Healthy individuals do not usually display symptoms. When symptoms do occur, 
they are usually mild, resembling infectious mononucleosis, and include the 
following: 
 Enlarged lymph nodes  
 Muscle pains  
 Fever that comes and goes  
 General sick feeling  
1.8 (iii) Trachoma 
    Definition 
Trachoma is an eye infection caused by Chlamydia trachomatis, which may 
result in    chronic scarring and blindness if left untreated. 
Alternative Names 
Granular conjunctivitis; Egyptian ophthalmia  
Causes, incidence, and risk factors 
Trachoma is caused by infection with the bacteria Chlamydiatrachomatis. It has 
an incubation period of 5 to 12 days and begins slowly as conjunctivitis 
(irritation near the eye, "pink eye"), which if untreated may become chronic and 
lead to scarring. 
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If the eyelids are severely irritated, the eyelashes may turn in and rub against the 
cornea. This can cause eye ulcers, further scarring, visual loss, and even 
blindness. 
Trachoma occurs worldwide -- primarily in rural settings in developing 
countries. It frequently affects children, although the consequences of scarring 
may not be evident until later in life. While trachoma is rare in the United States, 
certain populations marked by poverty, crowded living conditions, and/or poor 
hygiene are at higher risk for this illness. 
Trachoma is acquired via direct contact with eye or nose-throat secretions from 
affected individuals or by contact with inanimate objects that are contaminated 
with these secretions, such as towels or clothes. In addition, certain flies that 
have fed on these secretions can transmit trachoma. 
Symptoms 
 Conjunctivitis  
 Discharge from the eye  
 Swollen eyelids  
 Turned-in eyelashes  
 Swelling of lymph nodes just in front of the ears  
 Cloudy cornea 
Signs and tests 
Trachoma is definitely diagnosed by detection of the organism or antigen in 
conjunctival scrapings or by isolation of the bacteria in culture. 
Treatment 
   Systemic therapy with oral antibiotics can prevent long-term complications if 
used early in the infection. Active antibiotics include erythromycin and its 
derivatives, or doxycycline. In certain cases, eyelid surgery for lid deformities 
may be needed to prevent chronic scarring which can lead to blindness if not 
corrected 
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Expectations (prognosis) 
Early treatment before the development of scarring and lid deformities has an 
excellent prognosis. 
Complications 
 Scarring of the conjunctiva and cornea  
 Lid deformities  
 Turned-in eyelashes  
 Visual loss -- if severe, may result in blindness 
Calling your health care provider 
Call your health care provider if you or your child recently visited an area of the 
world where trachoma is common and there are symptoms of conjunctivitis. 
Prevention 
Trachoma is spread by direct contact with eye, nose, and throat secretions from 
affected individuals or by contact with objects that may have been in contact 
with these secretions. 
Improved sanitation and not sharing toilet articles such as towels are important 
measures for limiting the spread/acquisition of trachoma. 
1.9. (iv) Mycobacterium Avium Complex (MAC) 
Definition 
MAC, formerly known as MAI, stands for Mycobacterium Avium Complex. 
MAC is a group of mycobacteria (the two most common being M. avium and 
M. intracellulare), that cause a serious disease in people with advanced AIDS. 
MAC most often causes a disseminated illness (bacteria is spread though the 
blood stream) and can cause many symptoms throughout the body. 
MAC bacteria are found in air, water, soil, foods, some tobacco products, and in 
many animals. It is impossible to avoid contact with MAC bacteria. A recent 
study showed that person-to-person transmission of MAC bacteria is unlikely. 
 
Risk factor  
Risk factors for developing MAC include having fewer than 50 CD4 cells, a 
high viral load (greater than 90,000 copies per/ml), and having had another 
opportunistic infection such as CMV (cytomegalovirus). 
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Before HAART (Highly Active Antiretroviral Therapy), also known as the 
"cocktail," the number of people with AIDS who developed MAC reached as 
high as 40 percent. Since HAART, the number of people getting MAC has 
greatly declined. 
 Signs and symptoms  
MAC can infect a person's entire body. The signs and symptoms of MAC can be 
the same signs of other diseases. They include high fever, drenching sweats, 
diarrhea, weight loss, abdominal pain, fatigue, weakness, anemia (low levels of 
red blood cells), neutropenia (low levels of white blood cells) or 
thrombocytopenia (low levels of platelets), and elevated liver function tests. The 
liver or spleen may be enlarged. Blood infections, hepatitis, skin lesions, and 
pneumonia may also occur. 
 Treatment  
A doctor will usually give you a blood test to see if you have MAC. Although 
the blood test is the best test at this time, sometimes other tests are needed. Other 
tests may include stool samples and biopsies of the liver, digestive tract (gut), 
bone marrow, or other organs. Biopsies involve taking a sample of an organ 
using a big needle. Biopsies can be painful but are more reliable than stool 
samples. 
Prevention  
Yes, there are medications available that can help reduce one's risk of 
developing MAC. Preventive medication, also called prophylaxis, is 
recommended for anyone who is HIV-positive and has 50 CD4 cells or less. 
While rifabutin, clarithromycin, and azithromycin are all approved drugs for 
prophylaxis of MAC, clarithromycin and azithromycin are the preferred choices. 
You should talk with your doctor to see which one of these medications is best 
for you. 
Treatment  
Treatment for MAC involves taking a combination of antibiotics. MAC 
treatment must include at least two drugs, one of which should be either 
clarithromycin or Azithromycin. Ethambutol is the recommended second drug. 
Rifabutin, ciprofloxacin, or amikacin may be added for people with more severe 
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MAC. All of the drugs are pills except amikacin, which is given intravenously 
(IV). 
In cases where people with MAC either do not respond to treatment at all or 
relapse after first responding to treatment, many doctors recommend a type of 
drug test that checks to see if the medications will work on the type of MAC a 
person has. This is called a drug susceptibility test. Susceptible means that the 
drugs will likely work, while resistant means that the drugs probably will not 
work. Susceptibility testing is recommended mainly for clarithromycin, 
azithromycin, and rifabutin, though other drugs might be tested as well. 
MAC and the drugs used for treatment are hard on the body. You might consider 
visiting a nutritionist when you are first diagnosed with MAC so you can keep 
your weight up and prevent wasting. There are also medications available to help 
ease common MAC symptoms such pain, nausea, vomiting, and diarrhea, so do 
not be shy in asking for them. 
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1.10 Introduction of product Development 
              Product development usually begins when the active chemical entity has 
been shown to process the necessary attributes for a commercial product. 
Generally product development activities can be sub divided into formulation 
development and process development. 
1.10.1 Formulation Development
1
 
              Formulation development provides the basic information on the active 
chemical, the formula and the impact of raw materials or excipients on the 
product. A typical supportive data generated during these activities may include: 
1. Preformulation profile, which includes all the basic physical or chemical 
information about   the chemical entity. 
2.  Formulation profile, which consist of physical and chemical characteristics 
required for the product, drug excipients compatibility studies, and effect of 
formulation on in-vitro dissolution. 
3.  Effect of formulation variable on the bioavailability of the product. 
4.  Specific test methods. 
5.  Key product attributes and specification 
6.  Optimum formulation 
 Formulation development should not be considered complete until all those 
factors which could significantly alter the formulation have been studied. 
Subsequent minor changes to the formulation, however, may be acceptable, 
provide they are thoroughly tested and as shown to have no adverse effect on 
product characteristics. In case of drug development process, compound tested is 
only one. A variety of studies must be performed for this single drug, each 
designed to characterize its efficacy, safety, selectivity or purity. Much of the 
data generation is driven by strict and extensive regulatory control and in this 
most of the studies are interdependent. 
  Objective: - The overall objective of a drug development process is to move 
product candidate through development so that a new drug applicant (NDA) or 
product license application (PLA) can be submitted as quickly as possible with 
best chance of approval. 
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1.10.2 Pharmaceutical issues in drug development 
A) Role of excipients in drug development: - The bulk of final product in dosage 
form such as tablet, capsule etc the speed of disintegration, rate of dissolution/ 
release of drug, protection against moisture and stability during storage, as well 
as compatibility are determined by the excipients. Various excipients used are 
adhesives, absorbent excipients, liquid excipients, diluents, fillers, disintegrates, 
etc. 
► The general characteristics of excipients are: - 
 Must not react with drug substance. 
 No effect on function of other excipients. 
 Not interfere with the bioavailability of active material nor influence dissolution of 
the product. 
 No pharmaceutical or physiological activity. 
 Have consistent and stable chemical and physical characteristics & properties from 
batch to batch and ideally between suppliers. 
 Colorless and not support microbiological growth in the product. 
Performance characteristics of the excipient are 
 Functionality: The control of functionality is important because many excipients 
have multiple functions or sometimes there is lack of awareness in some situations 
that excipients behave differently. 
 Rework ability: The reworking potential is defined as the ratio of areas under the 
tensile strength compression profiles for re compression and for initial compression. 
Often the results show that recompression reduces tablet strength and that this 
reduction is more significant when the initial compaction is carried out at high 
pressure. 
 Response and force loading rate:  
 Modes of deformation: Tableting machines, which deform plastically with little 
elastic recovery, should produce better quality tablets than more resilient materials. 
 Effects on compression rate: Mostly strength of the tablets depend on the speed of 
rotary tablet press and hence on rate of tablet compression. In virtually all the cases, 
increase in tablet press speed led to a decrease in tablet strength. 
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B) Dosage form design 
 A rational approach to dosage form design for any drug requires a complete 
understanding of its physiochemical and biopharmaceutical properties which can 
have a tremendous impact on its bioavailability and thereby on its efficacy and 
toxicity profile. Properties that dictate the selection and formulation of dosage 
forms include: 
 Solubility and dissolution rate. 
 Partition coefficient. 
 Stability and/or degradation in physiologic fluids. 
 Susceptibility to metabolic inactivation. 
 Transport mechanism across biological membranes. 
C) In vitro correlation 
 In vitro dissolution tests seem to be the most sensitive and reliable predictors of 
in vivo availability. Invitro in vivo correlations are classified as pharmacological 
correlations, semi quantitative correlations and quantitative correlations. 
 Drug development also includes phase 1, 2 and 3 trials carried out on a particular 
group of people after analogue development and screening process. 
2.10.3 Process Development 
  Process development activities begin after the formulation has been developed. 
The process development should meet the following objectives: 
1.Develop a suitable process to produce a product which meets all: 
a. Product specifications 
b. Economic constrains 
c. cGMP 
2.Identify the key process parameters that affect the product attributes 
3.Identify in-process specification and test method 
4.Identify generic and specific equipment that may required. 
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PRODUCT DEVELOPMENT FLOWCHART 
Solid, Dosage Forms 
STAGE 1 
LITERATURE 
SEARCH 
      
   STAGE 2 
ACTIVE SOURCING 
     
STAGE 3 
ACTIVE EVALUATION 
    
Do not evaluate material   
 While still in a R & D stage                    STAGE 4 
 Use only production activity        ACTIVE PURCHASING                     
PREFORMULATION                                                                         STAGE 
     STAGE 5 
       ACTIVE TESTING 
     
STAGE 6 
INNOVATOR PRODUCT PURCHASING 
Purchase a new lot                                 
Lot number every 3 mth                
From the smallest to the                  STAGE 7 
Largest pack size          INNOVATOR PRODUCT TESTING 
(in each dosage strength )                       
STAGE 8 
BULK ACTIVE TESTING 
 
STAGE 9 
Excipient Evaluation 
Residual solvent Check                                           
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                                   
                                                   STAGE 10 
Container Closure 
System Choices 
                                                            
                                                                         STAGE 11                  DEVELOPMENT BATCHES 
Manufacturing Process Evaluation 
                                                           
                                                    STAGE 12 
Bulk Active Purchase 
                                                             
                                                     STAGE 13 
Analytical Evaluation 
  
                                                  STAGE 14 
Prepared full written protocol          Process Optimization 
For PO scale up & PQ batches         PO Batch 
  
STAGE 15 
                                    Analytical development                 PROCESS OPTIMIZATION 
 
STAGE 16. 
SCALE – UP 
 
STAGE 17 
PROCESS 
QUALIFICATION 
 
                                                                   STAGE 18                                      PIVOTAL BATCHES 
PIVOTAL BATCH 
PRODUCTION 
 
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  STAGE 19                       
                                                                                                     BIO-EQUIVALENTS                                                                                                                                                                                                                                                                                                                                                         
                                  BIO STUDY EVALUATION                    STUDY 
   
Review all raw data development              STAGE 20 
& lab note book. Evaluate all interim     ANDA PRE-SUBMISSION 
Report that from part of the                         AUDIT 
 
Product Development Report                          
                                                                                                       SCOPE OF PRODUCT                                                                                                 
                                                                       STAGE 21                    Development                                                        
              ANDA SUBMISSION 
             
            STAGE 21 B 
PRODUCT DEVELOPMENT REPORT    
           
Process validation                                 STAGE 22 
Signify the first THREE                Process Validation & 
Consecutive production                    Statistics                            Process Validation 
Lots (same batches size and       (3 commercial lots) 
         Active lot no )                                 
STAGE 23 
Process Revalidation 
After a major change 
(Check SUPAC) 
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1.11. Process development can be divided into several stages 
a) Design 
b) Ranging 
c) Characterization 
d) Verification 
 a) Design 
 This is the initial planning stage of process development. During this stage, 
technical operation in both the manufacturing and quality-control departments 
should be consulted. The practically and the reality of the manufacturing 
operation should be kept in perspective. 
 Key documents for the technical definition of the process are the flow diagram, 
the cause and effect diagram and the influence matrix. 
 The flow diagram provides a convenient basic on which to develop a detailed list 
of variables and responses. Preliminary working documents are critical, but they 
should never be ―cast in stone‖, since new experimental data may drastically 
alter them. The final version will eventually be an essential part of the process 
characterization and technical transfer documents. Regardless of the stage of 
formulation/process development being considered, a detail identification of 
variables and response is necessary for early program planning. 
 As the development program progresses, new discoveries will provide an update 
of the variable and responses. It is important that current knowledge be 
adequately summarized for the particular process being considered. It should be 
pointed out, however that common sense and experience must be used in 
evaluating the variable during process design and development. 
 An early transfer of the preliminary documentation to the manufacturing and 
quality control department is essential, so that they can being to prepare for any 
new equipment or facilities that may required. 
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b)  Ranging 
 Process-ranging studies will test whether identified parameter are critical to the 
product and process being developed. These studies determined the:  
a. Feasibility of the design process  
b. Criticality of the parameter 
c.      Failure limits for each of the critical variable 
d. Validity of the test methods 
This is usually a transition stage between the laboratory and the projected final 
process. 
c) Characterization 
 Process characterization provides a systematic examination of critical variables 
found during process ranging. The objectives of these studies are:  
a) Confirm key process control variables and quality their effect on product 
attributes. 
b) Establish product conditions for each unit operation. 
c) Determine in process operating limits to guarantee acceptable finished product 
and yield. 
d) A carefully planned and coordinate experimental program is essential in order to 
achieve this objective. 
d) Verification 
Prior to a process being scale-up and transferred to production, verification is 
required. This ensures that it behave as designed under simulated production 
conditions and Determines its reproducibility. Key elements of the process-
verification runs should be evaluated using well-designed in-process sampling 
procedure. These should be focused on potentially critical unit operations. 
Validated in-process and final product analytical procedures should always be 
used. Sufficient replicate batches should be produced to determine between and 
within-batch variations. 
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The typical process verification analysis of a tableted product include 
Table NO: 2.1 
Unit Operation Analysis 
Pre-blending 
Blend uniformity, Dry-mix, Water content by KF 
apparatus 
Granulation None required 
Sizing 
Granules size distribution, Milled Granules-Water 
content by KF apparatus. 
Blending 
Blend uniformity, Flow properties 
Potency/assay 
Tableting 
Average weight 
Hardness 
Thickness 
Disintegration 
Dissolution 
Friability 
      
The transfer procedure that is followed in order to pass the documented 
knowledge and experience gained during development and commercialization to 
an appropriate, responsible and authorized party. Technology transfer embodies 
both the transfer of documented and demonstrated technology, to the satisfaction 
of all parties and any and all applicable regulatory bodies.  
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1.12 Technology transfer subdivided into two units
6
:  
o Sending unit 
o Receiving unit     
● Advantages: 
 The transfer of technology from R & D (sending unit) to manufacturing 
(Receiving unit) is the first key steps to getting a high quality product to the 
market place. 
 The transfers of the process technology from the R & D bench to large scale 
manufacturing present some unique challenges. 
 It also useful to make a timeframe of the process for that particular product. 
 Hold time studies is useful for the planning of the product with other batches.  
● Objectives:  
    To describe the appropriate information set that needs to be complied to 
support the transfer of the information and provide regulatory filing 
documents.  
 To provide guidance on effective approaches for ensuring this information is 
available at ―print of use‖ where guidance on specific topic already exists 
this will be referred. 
 The technology transfer guide is planning in such a way that technology 
transfer performed in accordance with the recommendations in this guide 
will be the regulatory authorities.  
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1.12.1 Process Optimization
5
: 
              In the environment of increasing international competition where counters 
with lower production cost luckily catch up technologically, new thinking is 
required in order to meeting the competition is to focus on maximizing the 
utilization of exiting technology. This means much more than just investing in 
new equipment. 
              The ability to optimize or improve a process is dependent upon the ability 
to control the process. The ability to control the process is dependent upon the 
access to reliable and valid management.             
The ability to control the processor. The ability to optimize the process is depend 
upon the access to reliable and valid managements. A successful industrial 
organization thus entails a strategic approach encompassing the whole chain. 
A)  Need for Optimization 
             In an environment of increasing competition where countries with lower 
production cost, quickly catch up technologically, new thinking is required in 
order to meet the competition. Efficient organization and leadership is more 
difficult to copy than technology. A successful way of meeting the increasing 
competition can thus be to focus the effort on adapting the organization for 
maximal utilization of existing technology and faster than competitors, being 
able to continuously introduce and make use of new technology. 
B) Optimization Technology 
There are two type optimization problems. They are: 
1.  Constrained Optimization: 
  Constrains are those restricted placed on the system due to physical 
limitation. 
  (Ex: Economic consideration)  
2.  Unconstrained Optimization: 
 In unconstrained optimization problems there are no restriction (such as tablet    
hardness and disintegration). 
An additional complication in pharmacy is that formulations are not usually 
simple system. They often contain many ingredients and variables, which may 
interact with one another to produce unexpected. 
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1.12.3 Scale Up & Technology Transfer Consideration
7
 
 Scale up means increase the batch size; it acts a link between the formulation 
research development and production. 
The pilot plant and its staff play a critical role in technology evolution scale-up 
and transfer activity of new products. 
 These activities being early in the development cycle and include technical aspects 
of process development and scale-up, organization and responsibility of technology 
transfer team, documentation of transfer process, and obtain preparation for an FDA 
pre-approval inspection. A properly design and operated pilot plant enhance the 
collection of scientific data necessary to support internal transfer activities as well as 
regulatory submission and FDA pre-approval inspection. 
 Four key technical aspects must be addressed during scale-up in the pilot plant. 
Identification and control of critical component and formulation variables early 
in the development. 
  Pilot plant equipment that simulates as closely as possible equipment used at 
    The manufacturing site. 
Identification of critical process parameter and operating ranges with pilot plant 
equipment through the use of engineering and regret ion models.  
Collection of product and process data to adequately characterized each unit 
operation. 
The success of any program is highly dependant on the effectiveness of the 
communication presiding its implementation. Therefore, the preparation and 
distribution of a complete document summarizing the raw material and 
equipment requirements, manufacturing and packing process, process validation 
protocol, QC processor, safe handling processor as well as a detail plan of action 
out limiting expected result and time framer must be distributes prior to scale-up 
experiences. 
 The three main considerations to be address during an effective technology transfer 
of plan. The person involved and process steps. Once prepared, the plan must be 
communicated to the involved part in research, at the corporate level and at the 
production site. 
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 The facility design plan a critical role in addressing each of their technical aspects, 
however scientific and pilot plant staff involved in manufacturing operations with in 
the pilot facility also play a key role in ensuring smooth and timely transfer of 
process technology to the manufacturing site. 
 In the part, the transfer of formulation and, manufacturing technology was some 
times discretely processed from development staff with little interaction. Today, 
however, it is commonly recognize the interaction of these groups at an early 
development stage is critical in obtaining an efficient and successful transfer. 
 Scientific and pilot plants staff a key role in demonstrating new product 
manufacturing techniques to produce personal in the pilot plant environment. 
 A team orientation approach to the manufacture of pilot or large scale batches in the 
pilot plant will allow key production site personnel to view and comment on the 
process and make a specific recommendation for improvement based on the 
knowledge of the manufacturing site. 
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1.12.4 Introduction of Immediate Release Dosage Form: 
Oral route of drug administration is perhaps the most appealing route for the delivery of 
drugs.
8
 Of the various dosage forms administered orally, the tablet is one of the most 
preferred dosage forms because of its ease of manufacturing, convenience in 
administration, accurate dosing, stability compared with oral liquids, and because it is 
more tamperproof than capsules.
9, 10
 The bioavailability of drug is dependent on in vivo 
disintegration, dissolution, and various physiological factors. In recent years, scientists 
have focused their attention on the formulation of quickly disintegrating tablets. The 
task of developing rapidly disintegrating tablets is accomplished by using a suitable 
diluent and superdisintegrant. 
The gastrointestinal tract provides sufficient fluid to facilitate disintegration of the 
dosage form and dissolution of the drug. The large surface area of gastric mucosa favors 
the drug absorption. Therefore, the oral route has continued to be the most appealing 
route for drug delivery despite the advancements made in the new drug delivery 
systems. Banker and Anderson stated that at least 90% of all drugs used to produce 
systemic effect are administered orally.
11
 Rapidly disintegrating tablets have received 
much attention in recent years, as they are preferred by pediatric and geriatric patients. 
Moreover, the drug dissolution is facilitated by the tablets quick disintegration. 
Bioavailability of a drug depends in absorption of the drug, which is affected by 
solubility of the drug in gastrointestinal fluid and permeability of the drug across 
gastrointestinal membrane. The drugs solubility mainly depends on physical – chemical 
characteristics of the drug. However, the rate of drug dissolution is greatly influenced by 
disintegration of the tablet. 
The drug will dissolve at a slower rate from a nondisintegrating tablet due to exposure 
of limited surface area to the fluid. The disintegration test is an official test and hence a 
batch of tablet must meet the stated requirements of disintegration. 
Disintegrants, an important excipient of the tablet formulation, are always added to 
tablet to induce breakup of tablet when it comes in contact with aqueous fluid and this 
process of desegregation of constituent particles before the drug dissolution occurs, is 
known as disintegration process and excipients which induce this process are known as 
disintegrants. 
The objectives behind addition of disintegrants are to increase surface area of the tablet 
fragments and to overcome cohesive forces that keep particles together in a tablet. 
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1.13. Mechanism of tablet Disintegrant 
12 
 
The tablet breaks to primary particles by one or more of the mechanisms listed 
below:- 
1) By capillary action 
2) By swelling 
3) Because of heat of wetting 
4) Due to disintegrating particle/particle repulsive forces 
5) Due to deformation 
6) Due to release of gases 
7) By enzymatic action 
1) By capillary action 
Disintegration by capillary action is always the first step. When we put the tablet 
into suitable aqueous medium, the medium penetrates into the tablet and replaces 
the air adsorbed on the particles, which weakens the intermolecular bond and 
breaks the tablet into fine particles. Water uptake by tablet depends upon 
hydrophilic of the drug /excipient and on tableting conditions. For these types of 
disintegrants maintenance of porous structure and low interfacial tension towards 
aqueous fluid is necessary which helps in disintegration by creating a 
hydrophilic network around the drug particles. 
2) By swelling 
Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling Tablets with high porosity show poor disintegration 
due to lack of adequate swelling force. On the other hand, sufficient swelling 
force is exerted in the tablet with low porosity. It is worthwhile to note that if the 
packing fraction is very high, fluid is unable to penetrate in the tablet and 
disintegration is again slows down. 
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Figure.1 disintegration of tablet by wicking and swelling 
3) Because of heat of wetting (air expansion) 
When disintegrants with exothermic properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps in disintegration of tablet. 
This explanation, however, is limited to only a few types of disintegrants and can 
not describe the action of most modern disintegrating agents. 
4) Due to disintegrating particle/particle repulsive forces 
Another mechanism of disintegration attempts to explain the swelling of tablet 
made with ‗non-swellable‘ disintegrants. Guyot-Hermann has proposed a 
particle repulsion theory based on the observation that no swelling particle also 
cause disintegration of tablets. The electric repulsive forces between particles are 
the mechanism of disintegration and water is required for it. Researchers found 
that repulsion is secondary to wicking. 
5) Due to deformation. 
Hess had proved that during tablet compression, disintegrated particles get 
deformed and these deformed particles get into their normal structure when they 
come in contact with aqueous media or water. Occasionally, the swelling 
capacity of starch was improved when granules were extensively deformed 
during compression. This increase in size of the deformed particles produces a 
break up of the tablet. This may be a mechanism of starch and has only recently 
begun to be studied. 
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    Figure.2. disintegration by deformation and repulsion:  
6) Due to release of gases 
Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid. The tablet 
disintegrates due to generation of pressure within the tablet. This effervescent 
mixture is used when pharmacist needs to formulate very rapidly dissolving 
tablets or fast disintegrating tablet. As these disintegrants are highly sensitive to 
small changes in humidity level and temperature, strict control of environment is 
required during manufacturing of the tablets. The effervescent blend is either 
added immediately prior to compression or can be added in to two separate 
fraction of formulation. 
7) By enzymatic reaction 
Here, enzymes presents in the body act as disintegrants. These enzymes destroy 
the binding action of binder and helps in disintegration. 
  Table.2.2.1. Disintegrating enzymes 
Enzymes Binder 
Amylase Starch 
Protease Gelatin 
Cellulose Cellulose and its derivatives 
Invertase Sucrose 
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Methods of addition of Disintegrants 
 
The method of addition of disintegrants is also a crucial part. Disintegrating agent can 
be added either prior to granulation (intragranular) or prior to compression (after 
granulation i.e. extragranular) or at the both processing steps. Extragranular fraction of 
disintegrant (usually, 50% of total disintegrant requires) facilitates breakup of tablets to 
granules and the intragranular addition of disintegrants produces further erosion of the 
granules to fine particles. 
1.13.1 Types of Disintegrants 
1) Starch 
Starch was the first disintegrating agent widely used in tablet manufacturing. Before 
1906 potato starch and corn starch were used as disintegrants in tablet formulation. 
However, native starches have certain limitations and have been replaced by certain 
modified starches with specialized characteristics. 
The mechanism of action of starch is wicking and restoration of deformed starch 
particles on contact with aqueous fluid and in doing so release of certain amount of 
stress which is responsible for disruption of hydrogen bonding formed during 
compression. 
Lowenthal & Wood proved that the rupture of the surface of a tablet employing starch 
as disintegrant occurs where starch agglomerates were found. The conditions best suited 
for rapid tablet disintegration are sufficient number of starch agglomerates, low 
compressive pressure and the presence of water. 
The concentration of starch used is also very crucial part. If it is below the optimum 
concentration then there are insufficient channels for capillary action and if it is above 
optimum concentration then it will be difficult to compress the tablet. 
2) Pregelatinized starch 
Pregelatinized starch is produced by the hydrolyzing and rupturing of the starch grain. It 
is a directly compressible disintegrants and its optimum concentration is 5-10%. The 
main mechanism of action of Pregelatinized starch is through swelling. 
3) Modified starch 
To have a high swelling properties and faster disintegration, starch is modified by 
carboxy methylation followed by cross linking, which is available in market as cross 
linked starch. One of them is sodium starch glycolate. Even low andsubstituted 
carboxymethyl starches are also marketed as Explotab Primojel®. 
Mechanism of action of this modified starches are rapid and extensive swelling with 
minimum gelling. And its optimum concentration is 4-6 %. If it goes beyond its limit, 
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then it produces viscous and gelatinous mass which increases the disintegration time by 
resisting the breakup of tablet. They are highly efficient at low concentration because of 
their greater swelling capacity. 
Table.2.2.2 List of disintegrants 
Disintegrations 
Concentration  in 
granules 
(%w/w) 
Special comments 
 
Starch USP 5-20 
Higher amount is required, 
poorly compressible 
Direct compression 5-15 -- 
Avicel
®
(PH 101, PH 102) 10-20 
Lubricant properties and 
directly compressible 
Solka floc
®
 5-15 Purified wood cellulose 
Alginic acid 1-5 Acts by swelling 
Na alginate 2.5-10 Acts by swelling 
Explotab
®
 2-8 
Sodium starch glycolate, 
superdisintegrant 
Polyplasdone
®
(XL) 0.5-5 Crosslinked PVP 
Amberlite
®
 (IPR 88) 0.5-5 Ion exchange resin 
Methyl cellulose, Na CMC, 
HPMC 
5-10 -- 
AC-Di-Sol
®
 1-3 Direct compression 
4) Cellulose and its derivatives 
Sodium carboxy methylcellulose (NaCMC and CARMELLOSE sodium) has highly 
hydrophilic structure and is soluble in water. But when it is modified by internally 
crosslinking we get modified crosslinked cellulose i.e. Crosscarmellose sodium which is 
nearly water insoluble due to cross linking. It rapidly swells to 4-8 times its original 
volume when it comes in contact with water. 
5) Microcrystalline cellulose (MCC) 
MCC exhibit very good disintegrating properties because MCC is insoluble and act by 
wicking action. The moisture breaks the hydrogen bonding between adjacent bundles of 
MCC. It also serves as an excellent binder and has a tendency to develop static charges 
in the presence of excessive moisture content. Therefore, sometimes it causes separation 
in granulation. This can be partially overcome by drying the cellulose to remove the 
moisture. 
6) Alginates  
Alginates are hydrophilic colloidal substances which has high sorption capacity. 
Chemically, they are alginic acid and salts of alginic acid. Alginic acid is insoluble in 
water, slightly acidic in reaction. Hence, it should be used in only acidic or neutral 
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granulation. Unlike starch and MCC, alginates do not retard flow and can be 
successfully used with ascorbic acid, multivitamin formulations and acid salts of 
organic bases. 
7) Ion-exchange resin 
Ion exchange resin (Ambrelite®IPR-88) has highest water uptake capacity than other 
disintegrating agents like starch and Sodium CMC. It has tendency to adsorb certain 
drugs. 
8) Miscellaneous 
This miscellaneous category includes disintegrants like surfactants, gas producing 
disintegrants and hydrous aluminium silicate. gas producing disintegrating agents is 
used in soluble tablet, dispersible tablet and effervescent tablet. 
Polyplasdone®XL and Polyplasdone®XL10 act by wicking, swelling and possibly 
some deformation recovery. Polyplasdone®XL do not reduce tablet hardness, provide 
rapid disintegration and improved dissolution. Polyplasdone® as disintegrating agent 
has small  
Particle size distributions that impart a smooth mouth feel to dissolve quickly. Chewable 
tablet does not require addition of disintegrant. 
9) Superdisintegrants 
As day‘s passes, demand for faster disintegrating formulation is increased. So, 
pharmacist needs to formulate disintegrants i.e. Superdisintegrants which are effective 
at low concentration and have greater disintegrating efficiency and they are more 
effective intragranularly. But have one drawback that it is hygroscopic therefore not 
used with moisture sensitive drugs. 
And this superdisintegrants act by swelling and due to swelling pressure exerted in the 
outer direction or radial direction, it causes tablet to burst or the accelerated absorption 
of water leading to an enormous increase in the volume of granules to promote 
disintegration.                
 
Figure.2.2.3 mechanism of superdisintegrants by swelling 
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1.14 Factors affecting disintegration 
1) Effect of fillers 
The solubility and compression characteristics of fillers affect both rate and 
mechanism of disintegration of tablet. If soluble fillers are used then it may 
cause increase in viscosity of the penetrating fluid which tends to reduce 
effectiveness of strongly swelling disintegrating agents and as they are water 
soluble, they are likely to dissolve rather than disintegrate. Insoluble diluents 
produce rapid disintegration with adequate amount of disintegrants. Chebli and 
cartilier proved that tablets made with spray dried lactose (water soluble filler) 
disintegrate more slowly due to its amorphous character and has no solid planes 
on which the disintegrating forces can be exerted than the tablet made with 
crystalline lactose monohydrate. 
2) Effect of binder 
As binding capacity of the binder increases, disintegrating time of tablet 
increases and this counteracts the rapid disintegration. Even the concentration of 
the binder can also affect the disintegration time of tablet. 
3) Effect of lubricants 
Mostly lubricants are hydrophobic and they are usually used in smaller size than 
any other ingredient in the tablet formulation. When the mixture is mixed, 
lubricant particles may adhere to the surface of the other particles. This 
hydrophobic coating inhibits the wetting and consequently tablet disintegration. 
Lubricant has a strong negative effect on the water uptake if tablet contains no 
disintegrants or even high concentration of slightly swelling disintegrants. On 
the contrary, the disintegration time is hardly affected if there is some strongly 
swelling disintegrants are present in the tablet. But there is one exception like 
sodium starch glycolate whose effect remains unaffected in the presence of 
hydrophobic lubricant unlike other disintegrants. 
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4) Effect of surfactant                   
  Table.2.2.3 the effects of various surfactants 
Surfactant Remarks 
Sodium lauryl sulfate 
 
Good-various drugs Poor  - various drugs 
Polysorbate 20 Good 
Polysorbate 40 & 60 Poor 
Polysorbate 80 Good 
Tweens Poor 
Poly ethylene glycol Poor 
 
(Good – decrease in disintegration time, Poor – increase in disintegration time) 
Sodium lauryl Sulphate increased absorption of water by starch or had a variable 
effect on water penetration in tablets. Surfactants are only effective within 
certain concentration ranges. Surfactants are recommended to decrease the 
hydrophobicity of the drugs because the more hydrophobic the tablet the greater 
the disintegration time. Aoki and fukuda claimed that disintegration time of 
granules of water-soluble drugs did not seem to be greatly improved by the 
addition of nonionic surfactant during granulation , but the desired effect of a 
surfactant appeared when granule were made of slightly soluble drugs.  
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1.15 Antibacterial agent
42
       
             
Definition: These are agents which are used for the to kill or inhibit the bacteria.  
 
1.15.1Classification of antibacterial agent:    
         
The antibacterial agents are classified according to its mode of action. 
(A) Antibacterial agents which interfere with the synthesis or action of folate. 
1.  Sulphonamide 
2. Trimethoprim             
 (B) Beta-lactam antibiotics 
           1. Penicillin 
       2. Cephalosporins and Cephamycin 
        3. Other β – lactam antibiotics            
(C) Antibacterial agents affecting bacterial protein synthesis.  
                                           1. Tetracyclines 
                                          2. Chloramphenicol 
                                           3. Aminoglycosides 
                                          4. Macrolides                                              
                                                 i. Azithomycin 
                                                 ii. Erythromycin   
                            iii. Clarithomycin 
(D) Antibacterial agents affecting topoisomerase-2 
                                           1. Fluoroquinolones                                    
(E) Miscellaneous antibacterial agents                                      
                                           1. Glocopeptide 
                                          2. Polymixin antibiotics  
                                                     3. Bacitracin 
                                            4. Metronidazole 
                                             5. Nitrofurantion  
(F) Antimycobacterial agents for treat to tuberculosis. 
                                                      1. Streptomycin 
                                           2. Isoniazide 
                                              3. Rifampicin 
                                           4. Ethambutal 
                                            5. Pyrazinamide 
                                            6. Capreomycin 
                                           7. Cycloserine 
 (G)   Antimycobacterial agents for treat to leprosy 
                                           1. Dapsone 
                                                     2. Rifampicin 
                                                     3. Cloazimine 
 
 
 
 
 
 Chapter 1                                                                                                   Introduction 
 
Dept. of Pharmaceutics 43 JKK Nattraja College of Pharmacy 
 
 
1.15.2 Macrolides antibiotics    
      The macrolides are a large group of antibacterial mainly derived from 
Streptomycess spp.and having a common macrocyclic lactone ring to which one 
or more sugar is attached. They are all weak base and only slightly soluble in 
water .Their   properties are very similar and in general they have low toxicity 
and a similar spectrum of antimicrobial activity with cross-resistance b/w 
individual members of the group. The macrolides are bacteriostatic or 
bactericidal depending on the concentration and the type of       micro-organism 
and are thought to interfere with bacterial protein synthesis. Their antimicrobial 
spectrum is similar to that of benzyl penicillin but they are also active against 
such organisum as legionella pneumophila, mycoplasm pneumoniae and some 
rickettsias, chlamydias and chlamydophilas. 
                                    Macrolides and related drug have a postantibiotic effect; 
that is antibacterial activity persists after concentration have dropped below the 
minimum inhibitory concentration. 
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1.15.3 Biochemical reaction as potential target  
     Class -1 reaction:  
Class-1 reaction are not promising targets, for two reason. 
1
st
 – there is no very marked difference b/w bacteria and human cells in the 
mechanism for obtaining energy from glucose since both use the embden-
meyerh of pathway and the citric acid cycle. 
2
nd
 – even if the glucose pathways were to be blocked a large verity of other 
compounds (amino acids lactate etc). 
     Class-2 reaction 
           Class-2 reactions are better targets since some pathways involved in class-3 
reaction exust in parasitic but not in human cells. For instance human cells have 
in the course of evolution lost the ability possessed by bacteria to synthesis lost 
the ability  passed by bacteria to synthesis some amino acids the so called 
essential amino acids and also the growth factors or vitamins any such difference 
represents apotential target. Another type of target occur when a pathways is 
identical in both bacteria and man but has differential sensitivity to drug. 
 
 
Class-3 reaction 
            Class-3 reaction are particularly good targets for selective toxicity because 
every cell has to make its own macromolecules. These cannot be picked up from 
the environment and there are very distinct differences b/w mammalian cells in 
the pathways involved in class-3 reaction. In the class-3 reaction protein are 
synthesized. 
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1.15.4 Protein synthesis 
The ribosome are cytoplasmic nucleoprotein structures that are the basic 
units of machinery for the synthesis of protein on messenger RNA templates. 
They are different in eukaryotes and prokaryotes and this provides the basis for 
the selective antimicrobial action of some antibiotics. The bacterial ribosome 
consists of a 50s subunit and a 30s subunit. In this respect it differs from the 
mammalian ribosome which has a 60s and 40s subunit. A simplified version of 
protein synthesis in bacteria is as follows. Messenger RNA which is transcribed 
from DNA becomes attached to the 30s subunit of the ribosome which moves 
along the mRNA so that successive condones of the messenger pass along the 
ribosome from the right the ―A‖ position to the  left the ―P‖ position as show in 
,The ―P‖ site contains the graving peptide chain attached to a molecule of 
transfer RNA.The next amino acid residue to be added linked to its specific 
tRNA with its distinctive anticodon-moves into the A site being bound to the site 
by a codan,anticodon recognition, which occur by complementary base-pairing. 
A transpeptidation reaction occurs which links the incoming tRNA at the ‗A‘ 
site. The tRNA from which the peptide chain has removed is now ejected from 
the ―P‖ site. The tRNA at the A site is Tran located to the P site and the 
ribosome moves on one codon relative to the messenger. A new tRNA with 
amino acid attached and with the relevant anticodon now moves into the ―A‖ site 
and the whole process is repeated. 
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CHAPTER - 2 
1.0 AZITHROMYCIN DRUG PROFILE 
2.1 DRUG-PROFILE 
13, 14, 15, 16, 17 & 18
 
Azithromycin is a newer macrolide that was developed to overcome some of the 
shortcoming of erythromycin such as intolerance, pharmacokinetics, and limited 
antimicrobial pectrum.Azithromycin (technically an azalide) has a 15-
membered ring, which is derived from the insertion of an amino group into the 
erythromycin ring.Azithromycin has unique pharmacokinetics that give rise to 
prolonged tissue levels, which allow briefer duration of therapy(3to5 days) for 
most infections and a single-dose regimen of treatment of chlamydial STDs.It 
contain two molecules of water.  
 Chemical abstracts registry no         
      (i) For anhydrous-      [83905-01-5] 
      (ii) For dehydrate-     117772-70-0 
Chemical abstracts name:     
(2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2,6-dideoxy-3-C-methyl-3-
O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one 
Structure:                                                       
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2.1.1 Physical and chemical properties   
Mol. Formula 
Anhydrous 
Dihydrate 
 
C38H72N2O12 
C38H72N2O12. 2H2O 
Mol. Wt 
Anhydrous 
Dihydrate 
 
748.98 
785.0 
% Composition C- 60.94% 
H- 9.69% 
N-3.74% 
O- 25.63% 
 
State solid (crystalline power) 
 
Odor Odorless 
Taste not available 
M.P 113- 115 ºC (for anhydrous) 
126 ºC (for dihydrate) 
 
Color white 
 
pH 9.0 to 11.0 
 
Solubility Practically insoluble in water, freely soluble in 
anhydrous ethanol and in methylene chloride. 
 
Specific optical rotation -45 to -49 (anhydrous substance) 
Water contain 1.8% to 6.5% determined on 0.200g 
Sulphate ash maximum 0.2%, determined on 1.0gm 
Heavy metals maximum 25 ppm 
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Azithromycin Tablet:- 
Azithromycin Tablet contain not less than 90.0% and not more than 110.0% of 
the labeled amount of Azithromycin  
   Description:  
        White tablet or film coated tablets with White or almost white coar. 
    Identification 
Dissolve quantity of the powder tablets in ethanol to produce a solution 
of 10mg of Azithromycin/ml and filter, using successive filtrate as a test 
solution. Dissolve a quantity of Azithromycin LRS in ethanol to produce a 
reference solution of 10mg of Azithromycin/ml, the solution comply with test 
(1) for identification describe under Azithromycin.  
   Dissolution:         
   Carryout the dissolution test (method-2) using a phosphate BS (to 6000ml of 
0.1mol/L disodium hydrogen phosphate solution add 40ml of hydrochloric acid, 
adjust the ph value to 6.0) 900ml as the dissolution medium ,adjust the rotation 
speed of the paddle to 100 rpm.Withdraw the solution after exact 45 minute and 
filter. Dilute an accurately measured quantity of the successive filtrate with the 
same solvent to produce a solution of 55µg per ml ,as test solution .Triturate 10 
tablets to an accurately weight quantity equivalent to about the average wt of one 
tab add aquantity of ethanol(using 1ml of ethanol for 2mg of the labeled amount 
of Azithromycin) and the dissolution medium, shake for 30 minutes or ultrasonic 
ate for 10 minutes to dissolve Azithromycin.Dilute an accurately measured 
quantity of the successive filtrate with the dissolution medium to produce a 
solution of 55µg per ml and filter, using the successive filtrate as the reference 
solution. Measure accurately 5ml each of the two solution separately to two 
tubes with stoppers respectively and accurately 5ml of sulfuric acid solution 
(75→100) mix well, allow to stand for 30 minutes ,cool measure the absorbance 
of the resulting solution at 482nm.Calculate the dissolution of Azithromycin 
form each tablet not less than 75% is dissolve.  
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Assay:            
 Weigh accurately and triturates 10 tablets dissolve accurately weighed quantity 
equivalent to 0.25gm Azithromycin in 125ml of ethanol, dilute with sterile water 
to produce a solution of 1000unit per ml, mix well, carry out the assy describe 
under Azithromycin using the supernatant liquid. 
Storage:  
                Preserve in tightly closed container stored in dry place. 
References: 
1) Pharmacopoeia of  people’s republic of china Vol-II ,(2005)    
 
2. 2 Pharmacokinetics 
Absorption 
 Azithromycin given orally is about 40% bioavailability absorption from capsule, 
but not tablet is reduced by food. Peak plasma concentration are achieved 2-3 
hours after a dose but Azithromycin extensively distributed to the tissue and 
tissue concentration subsequently remain much higher than these in the blend. In 
contrast to other antibacterial plasma concentration is therefore, a little value as a 
guide to efficacy. High concentrations are taken of in to add blood cell. 
Azithromycin is more stable than erythromycin at gastric ph. The 
Pharmacokinetic profile of Azithromycin reflects a rapid and extensive uptake 
from the circulation into intracellular compartment, followed by slow release. 
Azithromycin has been show to penetrate tissues rapidly and extensively,steady-
state levels were 0.64µg/ml at 2 to 4hr,0.1µg/ml at 10 to 12hr,and 0.012µg/ml at 
72 to 96hr.Azithromycin remains in human polymorph nuclear leukocytes in 
vitro for several hr even after extra cellular drug has been removed ,and its 
release can be stimulated by phagocytosis. Azithromycin level in pulmonary 
macrophages, polymorphonuclear leukocyte, tonsillar tissue and genital or pelvic 
tissue remain increased for extended periods, with a mean tissue half –life of 2to 
4 days.  
 
 Chapter 2                                                                                                Drug Profile 
 
Dept. of Pharmaceutics                        50                      JKK Nattraja College of Pharmacy 
 
 
Distribution  
Azithromycin is distributes widely throughout the body, except to the brain and 
CSF. Azithromycin has unique pharmacokinetic properties include extensive 
tissue distribution and high drug concentration within cells(including 
phagocytes)resulting in much greater concentration of drug in tissue or secretion 
compared to simultaneous serum concentration. Tissue fibroblast acts as the 
natural reservoir for the drug in vivo. Protein binding is 50% at very low plasma 
concentration and less at higher concentration.. 
Metabolism and Excretion  
 A small amount of Azithromycin are demethylated in the liver and it is excreted 
in bile as unchanged drug and metabolites. About 6.0% of oral dose(representing 
about 20% of the amount in the systemic circulation) is excreted in urine. The 
terminal elimination half life 40 to 68hr is prolonged because of extensive tissue 
sequestration and dinding.  
2. 2.1 Resistance:  
Resistance to macrolides usually results from one of four mechanisms  
(i) Drug efflux by an active pump mechanism (en coded by mrsA, mefA, or mefE in 
staphylococci,group A. streptococci ,or S.pneumoniae, respectively. 
(ii)  Ribosomal protection by inducible or constitutive production of methylase 
enzyme, mediated by expression of ermA,ermB AND ermC, which modify the 
ribosomal target and decrease drug binding. 
(iii) Macrolides hydrolysis by esterases produced by enterobacteriaceae. 
(iv) Chromosomal mutation that alter a 50s ribosomal protein (found in B.sub ilis, 
complyobacter spp, mycobacteria and gram-positive cocci.     
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2.3 Mode of action   
Macrolide antibiotics are bacteriostatic agents that inhibit protein synthesis by 
binding reversibly to the 50s ribosomal subunit of sensitive 
organisum.Azithromycin appears to inhibit the translocation step where in the 
nascent peptide chain temporarily residing at the a site of the transferase reaction 
fails to move to the P or donar site alternatively macrolides may bind and cause a 
conformational change that terminates proteins synthesis by indirectly 
interfering with transpeptidation and translocation. Fig no.1 
                                                 
   
                                                             Fig no- 1 
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2.4 Side Effects 
Minor: Abdominal pain, diarrhea, dizziness, headache, nausea, or vomiting. 
These effects should disappear as your body adjusts to Azithromycin. 
Azithromycin can cause increased sensitivity to sunlight. It is important to avoid 
prolonged exposure to sunlight and sunlamps. Wear protective clothing, and use 
an effective sunscreen. 
If you feel dizzy or light-headed, sit or lie down for a while; get up slowly from 
a sitting or reclining position; and be careful on stairs. 
Major, palpitations, rash, rectal or vaginal itching, shortness of breath, swelling 
of the face or neck, sore throat, unusual bruising or bleeding, or yellowing of the 
eyes or skin. If your symptoms of infection seem to be getting worse rather than 
improving, you should contact your doctor. 
2.5 Drug- Interactions 
Azithromycin interacts with several medications: 
 Azithromycin may increase blood levels of aminophylline, theophylline, 
carbamazepine, cyclosporine, tacrolimus, disopyramide, phenytoin, digoxin, 
triazolam, phenobarbital, ergotamine, dihydroergotamine, or oral anticoagulants 
(blood thinners, such as warfarin) when they are used concurrently; this may lead to 
serious side effects. 
 Antacids containing aluminum or magnesium will decrease the efficacy of 
Azithromycin. Take antacids one hour before or two hours after your dose of 
Azithromycin. 
 Do not take Azithromycin if you are taking pimozide; increased adverse effects on 
the heart may result. 
Adverse reactions 
In clinical trials, most of the reported side effects were mild to moderate in severity 
and were reversible upon discontinuation of the drug. Approximately 0.7% of the 
patients from the multiple-dose clinical trials discontinued azithromycin therapy 
because of treatment-related side effects. Most of the side effects leading to 
discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, 
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diarrhea, or abdominal pain. Rarely but potentially serious side effects were 
angioedema and cholestatic jaundice 
Storage : 
 to store this medicine: 
 Keep out of the reach of children.  
 Store away from heat and direct light.  
 Store the pediatric suspension form of azithromycin in the refrigerator.  
 Do not store in the bathroom, near the kitchen sink, or in other damp places. Heat 
or moisture may cause the medicine to break down.  
 Do not keep outdated medicine or medicine no longer needed. Be sure that any 
discarded medicine is out of the reach of children 
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CHAPTER - 3  
1.0 3.1 AIM AND OBJECTIVE  
To develop formulation of pharmaceutical equivalent of formulation and product 
development of azithromycin tablets. 
  
Selection criteria of immediate release dosage form 
1.) longer half life 
2.) Poor solubility 
3.) To need the immediate action of the drug. 
4.) Absorption from mainly stomach. 
5.) Long elimination half life 
Azithromycin: 
 Azithromycin is Anti-bacterial agents. It is used for mainly MAC infection, 
community acquired pneumonia and trachoma disorders. Very low solubility in 
aqueous media & oral bioavailability is 37%.its half life is 68 hrs & clearance is 630 
ml/min. 
 As per literature it is observed that Azithromycin the newest generation of 
macrolides is as effective and better tolerated, and associated with a lower risk of 
adverse effects. 
 It is more stable in the gastric pH. 
 Azithromycin prevents bacteria from growing by interfering with their ability to 
make protein. 
 The macrolides antibiotics do not interfere with humans’ ability to make protein. 
 Azithromycin is effective against a wide variety of bacterial organisms. 
 Azithromycin has the advantage of shorter treatment regimens and improved 
tolerance. 
 For better bioavailability drug should release fast from formulation to media. 
This can be performing with a disintegrant agent. 
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 Physical properties show that poor flow properties so we can conclude about the 
key ingredients of our formulation to make a fast release tablet. 
 
In the development of Azithromycin tablet we using, Microcrystalline cellulose,  
Croscarmellose sodium, Pregelatinized starch, Sodium lauryl Sulphate, Syloid 
244 FP, Magnesium Stearate, Hypromelose, PEG-6000, Titanium di oxide. Pre-
formulation testing is the first step in rational development of dosage form of 
drug substance, in this study characterization of drug API is most important 
study, solubility study, practical size analysis of API, Bulk density, Tapped 
density, and compressibility of the API was done. For development of 
Azithromycin formulation known about the details of innovator product. To 
develop a non – infringing formulation of Azithromycin, which is stable and bio- 
equivalent to Zithromax of Pfizer. We select the dissolution media as per the 
U.S.P, phosphate buffer pH 6.0 with tripsin in 900 ml at 100 rpm, NLT 75 % 
dissolved in 45 minutes.  Accelerated stability testing was done as per the ICH 
guidelines and successful formulation was found highly stable in all respects.  
 
Keeping above factor in view it is aimed to develop formulation of 
pharmaceutical equivalent Azithromycin as an immediate release dosage form.  
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CHAPTER - 4 
LITERATURE REVIEW 
KM Olsen et al (2005)19 Intrapulmonary pharmacokinetics of Azithromycin in healthy 
volunteers given five oral doses. The intrapulmonary pharmacokinetics of oral 
Azithromycin were studied in 25 healthy volunteers, each of whom received an initial 
dose of 500 mg and then 250 mg once daily for four additional doses. Bronchoscopy, 
bronchoalveolar lavage, and venipuncture were performed 4, 28, 76, 124, 172, 244, 340, 
and 508 h after the first dose was administered. Azithromycin concentrations in 
epithelial lining fluid (ELF), alveolar macrophages, peripheral blood monocytes, and 
serum were measured by high-performance liquid chromatography. Azithromycin was 
extensively concentrated in cells and ELF. Drug concentrations in AMs (peak mean +/- 
standard deviation, 464 +/- 65 micrograms/ml) exceeded 80 micrograms/ml up to 508 h 
(21 days) following the first dose, while concentrations in PBMs (peak, 124 +/- 28 
micrograms/ml) exceeded 20 micrograms/ml up to 340 h (14 days). Azithromycin 
concentrations in ELF peaked at 124 h (3.12 +/- 0.93 micrograms/ml) and were 
detectable up to 172 h (7 days), when they were 20 times the concurrent serum 
concentrations. Although the clinical significance of antibiotic concentrations in these 
compartments is nuclear, the sustained lung tissue penetration and extensive phagocytic 
accumulation demonstrated in this study support the proven efficacy of azithromycin 
administered on a 5-day dosage schedule in the treatment of extra cellular or 
intracellular pulmonary infections.  
R Mason  ET AL (2012)20 Spectrum and mode of action of Azithromycin (CP-62,993), a 
new 15-membered-ring macrolide with improved potency against gram-negative 
organisms The macrolide antibiotic azithromycin (CP-62,993; 9-deoxo-9a-methyl-9a-
aza-9a-homoerythromycin A; also designated XZ-450 [Pliva Pharmaceuticals, Zagreb, 
Yugoslavia]) showed a significant improvement in potency against gram-negative 
organisms compared with erythromycin while retaining the classic erythromycin 
spectrum. It was up to four times more potent than erythromycin against Haemophilus 
influenzae and Neisseria gonorrhoeae and twofold more potent against Branhamella 
catarrhalis, Campylobacter species, and Legionella species. It had activity similar to that 
of erythromycin against Chlamydia spp. Azithromycin was significantly more potent 
versus many genera of the family Enterobacteriaceae; its MIC for 90% of strains of 
Escherichia, Salmonella, Shigella, and Yersinia was less than or equal to 4 
micrograms/ml, compared with 16 to 128 micrograms/ml for erythromycin. 
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Azithromycin inhibited the majority of gram-positive organisms at less than or equal to 
1 micrograms/ml. It displayed cross-resistance to erythromycin-resistant 
Staphylococcus and Streptococcus isolates. It had moderate activity against Bacteroides 
fragilis and was comparable to erythromycin against other anaerobic species. 
Azithromycin also demonstrated improved bactericidal activity in comparison with 
erythromycin. The mechanism of action of azithromycin was similar to that of 
erythromycin since azithromycin competed effectively for [14C] erythromycin 
ribosome binding sites. 
 Suhagia BN ET AL 
2 1
Determination of Azithromycin in pharmaceutical dosage forms 
by   spectrophotometric methodA simple and sensitive spectrophotometric method has 
been developed for determination of Azithromycin in its pharmaceutical dosage forms. 
In the proposed method, azithromycin is oxidized with potassium permanganate to 
liberate formaldehyde, which is determined in situ using acetyl acetone, in the presence 
of ammonium acetate. A yellow coloured chromogen was obtained, having absorption 
maxima at 412 nanometer. The method is found to be linear in the concentration range 
of 10-75 microgram per milliliter, with regression coefficient of 0.9978. Various 
parameters such as concentration of potassium permanganate and reagent, time required 
for oxidation, and maximum colour intensity were optimized. The method was 
validated, and can be used successfully to assay azithromycin in its pharmaceutical 
dosage forms viz. tablets, capsules and injections. 
  Hooda AK  ETAL 22Azithromycin in the treatment of gingival hyperplasia in renal 
allograft recipients of cyclosporineBackground: Gingival hyperplasia is a known 
complication of Cyclosporine therapy. We studied the efficacy of Azithromycin in the 
treatment of gum hyperplasia in renal transplant patients on follow-up in our center. 
Methods: All renal transplant recipients with symptomatic gum hyperplasia were given 
Azithromycin for a period of 5 days in a dose of 500 mg on day 1 followed by 250 mg 
OD on days 2-5. The ratio of crown height and width in each of the 8 incisors was 
measured before starting therapy, at 4 weeks and at 8 weeks after therapy. Results: 
There were 122 renal transplant recipients on our follow-up. Of these, 115 were on 
Cyclosporine. Out of these, 11 patients (Males 9, Females 2) had symptomatic gum 
hyperplasia (9.56 percent). The symptoms in patients with gum hyperplasia were pain 
and bleeding from the gums. The average duration on Cyclosporine therapy in these 
patients was 25.8 months (3 to 36 months). Symptomatic relief was seen in all patients 
after Azithromycin therapy. The average value of ratio of crown height and width 
increased from pre-treatment baseline of 1.06 plus 0.11 to 1.18 plus 0.11 (at 4 weeks) 
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and to 1.24 plus 0.09 at 8 weeks after therapy (p less than 0.001). The drug was well 
tolerated and none of the patients reported any side effects. There was no significant 
change in the creatinine level at 1 month after Azithromycin therapy. Cyclosporine C2 
assays done in 3 patients before and 4 weeks after therapy also showed no significant 
change. Conclusion: We conclude that Azithromycin is a safe and effective therapy for 
Cyclosporine induced gum hyperplasia. 
 Singhi MK et all 
23 
Comparison of oral Azithromycin pulse with daily Doxycycline in 
the treatment of acne vulgarisIntroduction: Oral Azithromycin has been advocated by 
some in the treatment of acne. However, its efficacy has not been established. Material 
and Methods: This non-randomized controlled trial was conducted on 70 outpatients 
with acne vulgaris to compare the efficacy and safety of Azithromycin and doxycycline 
in the treatment of inflammatory acne. In the first group, azithromycin was administered 
500 mg daily before meals for 3 consecutive days in a 10-day cycle, with the remaining 
seven days in each cycle being drug-free days. The second group was given doxycycline 
100 mg daily after meals. Topical erythromycin was prescribed to all patients. Clinical 
assessment was done at 10-day intervals for both the groups up to three months. We 
followed the severity index described by Michaelsson for assessment of outcome 
measures. Results: There was 77.26 percent improvement in Aazithromycin treated 
group in comparison to 63.74 percent in the doxycycline treated group. There was a 
statistically significant reduction in severity in the azithromycin treated group. 
Conclusion: The study showed that a combination of Azithromycin with topical 
erythromycin was significantly better than doxycycline with topical erythromycin in the 
treatment of acne vulgaris. The incidence and severity of side effects were also lower 
with Aazithromycin. 
 Ogale SB et al 
24
 Comparative evaluation of the efficacy and safety of Azithromycin 
and Roxithromycin in children suffering from otitis media An open, randomized, 
comparative study was undertaken to compare the efficacy and safety of Azithromycin 
(Kid tablets) with Roxithromycin (Kid tablets) in the treatment of otitis media in 
children. 51 patients of either sex, under 12 years and presenting with signs and 
symptoms of otitis media were included in the study. The patients were randomly 
assigned to two groups and received either Azithromycin tablet 10 mg/kg once daily for 
3 days or Roxithromycin tablet 2.5-5 mg/kg twice daily for 7 days. The daily mean 
severity scores measuring the ear discharge suggested that there was a statistically 
significant fall in the severity scores in the Azithromycin group from day 1 onwards, 
whereas of the other signs and symptoms showed a statistically significant fall from day 
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2 onwards in the Azithromycin group as compared to day 4 in the Roxithromycin group. 
Both Azithromycin and Roxithromycin were equally well tolerated by the children with 
only one incidence of rash in the Roxithromycin group. 77 percent of the patients in the 
Azithromycin group were assessed as being cured as compared to only 36 percent of 
patients in the Roxithromycin group. 23 percent of patients in the Azithromycin group 
had improved as compared to 64 percent of patients in the Roxithromycin groups. The 
advantages of Azithromycin in the treatment of otitis media include broad spectrum of 
activity, pharmacokinetic properties that allow once daily dosing and short course 
therapy. Azithromycin is an appropriate choice for the treatment of otitis media in 
children. 
H. Rautelin1   et al 
25
Azithromycin resistance in Campylobacter jejuni and 
Campylobacter coliAbstract The MICs of erythromycin, Azithromycin and 
ciprofloxacin were determined for 60 human fecal isolates ofCampylobacter. Of these, 
30 strains selected on the basis of their resistance to erythromycin by disk diffusion 
were highly resistant to both erythromycin and Azithromycin. Nine of these selected 
isolates were resistant to ciprofloxacin. The remaining 30 strains were non-selected, 
consecutive isolates ofCampylobacter susceptible to erythromycin by disk diffusion and 
were shown to be two- to five-fold more susceptible to Azithromycin than to 
erythromycin as determined by MIC testing. 
R. Haye1   et al 26 Azithromycin versus placebo in acute infectious rhinitis with clinical 
symptoms but without radiological signs of maxillary sinusitis Abstract  In this double-
blind, parallel-group, multicenter study, 169 patients with symptoms of maxillary 
sinusitis but without radiographically confirmed empyema (pus) were randomly 
assigned to receive either 500 mg Azithromycin once daily for 3 days (87 patients) or 
placebo daily for 3 days (82 patients). Nasal secretion, maxillary tenderness and pain, 
nasal obstruction, general malaise, and hyposmia were assessed at the start of the study 
and on days 4, 11, and 25 of treatment. After 11 days 58% of the patients in the 
Azithromycin group were cured versus 31% in the placebo group; after 25 days the cure 
rate was 79% versus 67%, respectively. When both cure and improvement were 
considered, the corresponding figures after day 25 were 90% and 88%, respectively. 
Adverse events, predominantly gastrointestinal, occurred in 24 (27%) of the 
Azithromycin-treated patients and in 15 (18%) of those treated with placebo, but the 
difference was not statistically significant. There was a difference in efficacy in favor of 
Azithromycin in the treatment of rhinitis with symptoms of maxillary sinusitis but 
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without radiological signs of empyema (pus). Antibiotics should only be used to 
alleviate symptoms in patients with moderate to severe symptoms, as the results after 25 
days for both improvement and cure are equal. In the treatment of acute rhinitis with 
symptoms and signs of maxillary sinusitis but without empyema, treatment with 
Azithromycin seems to result in a better cure rate after 10–12 days when compared with 
placebo. 
J Retsema,  et al 
27 
Spectrum and mode of action of Azithromycin (CP-62,993), a new 
15-membered-ring macrolide with improved potency against gram-negative 
organisms.The macrolide antibiotic Azithromycin (CP-62,993; 9-deoxo-9a-methyl-9a-
aza-9a-homoerythromycin A; also designated XZ-450 [Pliva Pharmaceuticals, Zagreb, 
Yugoslavia]) showed a significant improvement in potency against gram-negative 
organisms compared with erythromycin while retaining the classic erythromycin 
spectrum. It was up to four times more potent than erythromycin against Haemophilus 
influenzae and Neisseria gonorrhoeae and twofold more potent against Branhamella 
catarrhalis, Campylobacter species, and Legionella species. It had activity similar to that 
of erythromycin against Chlamydia spp. Azithromycin was significantly more potent 
versus many genera of the family Enterobacteriaceae; its MIC for 90% of strains of 
Escherichia, Salmonella, Shigella, and Yersinia was less than or equal to 4 
micrograms/ml, compared with 16 to 128 micrograms/ml for erythromycin. 
Azithromycin inhibited the majority of gram-positive organisms at less than or equal to 
1 micrograms/ml. It displayed cross-resistance to erythromycin-resistant 
Staphylococcus and Streptococcus isolates. It had moderate activity against Bactericides 
fragilis and was comparable to erythromycin against other anaerobic species. 
Azithromycin also demonstrated improved bactericidal activity in comparison with 
erythromycin. The mechanism of action of azithromycin was similar to that of 
erythromycin since Azithromycin competed effectively for [14C] erythromycin 
ribosome binding sites. 
Sivasubramanian L  et al 28  Visible spectrophotometric methods for the determination 
of Azithromycin in tabletsTwo visible spectrophotometric methods have been 
developed for the estimation of Azithromycin in pure and in pharmaceutical 
formulations. The first method (A), a visible spectrophotometric method was based on 
the formation of a red colored chromogen with ferric chloride and 1,10-phenanthroline, 
which showed absorbance maximum at 490 nm and Beer's law was obeyed in the 
concentration range of 2.5-15 micro-g/ml. The second method (B) was based on the 
formation of a blue colored chromogen with Folin-Ciocalteau reagent, which showed 
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maximum absorbance at 720 nm and Beer's law was obeyed in the concentration range 
of 25-150 micro-g/ml. Results of analysis for both the methods were validated 
statistically and by recovery studies. ottom of Form 
  3. 2 Review of work done of Immediate Release dosage form 
Becker C, Dressman JB, et al 29 Biowaiver monographs for immediate release solid oral 
dosage forms: IsoniazideBecker C et al Literature data relevant to the decision to allow 
a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release 
(IR) solid oral dosage forms containing isoniazid as the only active pharmaceutical 
ingredient (API) are reviewed. Isoniazid's solubility and permeability characteristics 
according to the Biopharmaceutics Classification System (BCS), as well as its 
therapeutic use and therapeutic index, its pharmacokinetic properties, data related to the 
possibility of excipient interactions and reported BE/bioavailability (BA) problems were 
taken into consideration. Isoniazid is "highly soluble" but data on its oral absorption and 
permeability are inconclusive, suggesting this API to be on the borderline of BCS Class 
I and III. For a number of excipients, an interaction with the permeability is extreme 
unlikely, but lactose and other deoxidizing saccharides can form condensation products 
with isoniazid, which may be less permeable than the free API. A biowaiver is 
recommended for IR solid oral drug products containing isoniazid as the sole API, 
provided that the test product meets the WHO requirements for "very rapidly 
dissolving" and contains only the excipients commonly used in isoniazid products, as 
listed in this article. Lactose and/or other deoxidizing saccharides containing 
formulations should be subjected to an in vivo BE study. 
Dumont ML  et al 30 Probability of passing dissolution acceptance criteria for an 
immediate release tablets Dumont ML et al During development of solid dosage 
products, a pharmaceutical manufacturer is typically required to propose dissolution 
acceptance criteria unless the product falls into Biopharmaceutics Classification System 
(BCS) class I, in which case a disintegration test may be used. At the time of filing the 
new drug application (NDA) or common technical document (CTD), the manufacturer 
has already met with regulatory agencies to discuss and refine dissolution strategy. The 
dissolution acceptance criteria are based on stability and batch history data and are often 
arrived at by considering the percentage of batches that pass United States 
Pharmacopeia (USP) criteria at Stage 1 (S(1)), when in fact, the product is deemed 
unacceptable only when a batch fails USP criteria at Stage 3 (S(3)) [H. Saranadasa, 
Disso. Technol. 7 (2000) 6-7, 18 [1]]. Calculating the probability of passing (or failing) 
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dissolution criteria at S(1), S(2), or S(3) can assist a manufacturer in determining 
appropriate acceptance criteria. This article discusses a general statistical method that 
was developed to assess the probability of passing the multistage USP test for 
dissolution and how it was applied to an immediate release tablet formulation. In this 
case, acceptance criteria were set and the analysis was conducted to assess the 
probabilities of passing or failing based on this acceptance criterion. Whether the 
acceptance criteria were relevant to the product was also considered. This mathematical 
approach uses a Monte Carlo simulation and considers a range of values for standard 
deviation and mean of historical data. 
Qureshi SA  et al 31 Applications of a new device (spindle) for improved 
characterization of drug release (dissolution) of pharmaceutical products Qureshi SA et 
al a crescent spindle (patent pending) is described which may be used in place of the 
USP paddle component in USP dissolution apparatus 2. The new spindle is curve 
shaped, corresponding to the bottom of a dissolution vessel, with attached bristles to fill 
in the gap between the spindle and the surface of the vessel. The geometry of the new 
spindle provides more efficient mixing than the USP paddle and prevents accumulation 
of disintegrated material (no cone formation). Using the new spindle, in comparison 
with the USP paddle, dissolution characteristics of three drug products: 250 mg 
amoxicillin capsules, 15.6 g acetylsalicylic acid (ASA) boluses and 200 mg 
carbamzepine tablets were evaluated. The experimental conditions for dissolution 
testing with the two stirring devices included; 900 ml of 0.05 M phosphate buffer, pH 
6.8 with 50 rpm, 900 ml of 0.05 M acetate buffer, pH 4.5-ethanol (7:3) with 50 rpm, and 
water containing 1% sodium lauryl sulphate with 75 rpm for amoxicillin capsules, ASA 
boluses and carbamazepine tablets, respectively. Uncharacteristic of the test products, 
which are fast release, the USP paddle provides significantly slower drug release. For 
example, 90 min for <80% drug release vs. 10 min for >90% for amoxicillin capsules 
and 6 h for 80% vs. 30 min for >90% for ASA boluses with USP paddle vs. the new 
spindle. In case of the carbamazepine tablets, three products which are bioequivalent 
and prescribed interchangeably, the USP paddle method shows significantly different 
dissolution characteristics. However, with the new device, all these products show 
similar drug release characteristics, a better reflection of product release characteristics 
and in vivo drug release behaviour. Compared with the USP paddle, the suggested 
device (spindle) provides improved stirring and mixing which appears to provide more 
appropriate (biorelevant) characterization of pharmaceutical products. 
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Yu LX et al 
32
 we sought to evaluate whether U.S. Pharmacopeia (USP) apparatus 3 can 
be used as an alternative to USP apparatus 2 for dissolution testing of immediate-release 
(IR) dosage forms. Highly soluble drugs, metoprolol and ranitidine, and poorly soluble 
drugs, acyclovir and furosemide, were chosen as model drugs. The dissolution profiles 
of both innovator and generic IR products were determined using USP apparatus 2 at 50 
rpm and apparatus 3 at 5, 15, and 25 dips per minute (dpm). The dissolution profiles 
from USP apparatus 3 were compared to those from USP apparatus 2 using the f(2) 
similarity test. The dissolution profile from USP apparatus 3 generally depends on the 
agitation rate, with a faster agitation rate producing a faster dissolution rate. It was 
found that USP apparatus 3 at the extreme low end of the possible agitation range, such 
as 5 dpm, gave hydrodynamic conditions equivalent to USP apparatus 2 at 50 rpm. With 
appropriate agitation rate, USP apparatus 3 can produce similar dissolution profiles to 
USP apparatus 2 or distinguish dissolution characteristics for the IR products of 
metoprolol, ranitidine, and acyclovir. Incomplete dissolution was observed for the 
furosemide tablets using USP apparatus 3. Although it is primarily designed for the 
release testing of extended-release products, USP apparatus 3 may be used for the 
dissolution testing of IR products of highly soluble drugs, such as metoprolol and 
ranitidine, and some IR products of poorly soluble drugs, such as acyclovir. USP 
apparatus 3 offers the advantages of avoiding cone formation and mimicking the 
changes in physiochemical conditions and mechanical forces experienced by products in 
the gastrointestinal tract. 
 
 
 
 
 
 
 
 
 
 Chapter 4                                                                                          Literature Review 
 
Dept. of Pharmaceutics                        64                   JKK Nattraja College of Pharmacy 
 
 
Influence of higher rates of agitation on release patterns of immediate-release drug 
products
 
Shah VP et al 
33
 The dissolution procedure serves as a quality control test to assure 
batch-to-batch uniformity and bioequivalence of a product once the bioavailability of 
the product has been established. It can also be used to detect manufacturing and/or 
process variations that could reduce product bioavailability. Dissolution testing must be 
conducted at an appropriate agitation rate. Tests conducted at high agitation rates may 
lose the ability to differentiate between good and bad products. Although the effect of 
high agitation rates has been known for some time, several immediate-release drug 
products still have United States Pharmacopeia (USP) monograph dissolution 
procedures that require very high agitation rates. A systematic survey was conducted on 
marketed tablets of chloroquine phosphate, griseofulvin, hydroxychloroquine sulfate, 
isocarboxazide, primaquine phosphate, and sulfadiazine. Each of these products has a 
USP monograph requiring a dissolution test at a paddle speed of 100 rpm. To study the 
influence of agitation rate on the dissolution rate of these products, dissolution studies 
were conducted at paddle speeds of 50, 75, and 100 rpm with the USP apparatus 2 
(paddle method). The dissolution rate increased with an increase in the agitation rate 
from 50 to 75 rpm. However, no significant increase in the dissolution rate was noted 
with an increase in the agitation rate from 75 to 100 rpm. The data support the position 
that the higher agitation rate of 100 rpm is not necessary for a quality control procedure 
or a compendia standard for the products tested. 
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3 Patent Survey: 
 (i) Drug substance  
Patent no     Assignee/applicant Clues from the invention 
   US6268489 Pfizer    Monohydrate Azithromycin is hygroscopic. It is most difficult to 
prepare and maintain this monohydrate in a from having a 
contant,reproducible water content. it is particularly difficult to 
handle during formulation ,since at higher RH levels, the 
monohydrates readily picks up varying amount of water. Such 
problems have been over come by the present invention of stable 
dihydrate. 
   US7056893 Insite vision   Azithromycin antibiotic have a maximum stability over a ph 
interval of about 5.0 to 7.0 preferably with at a ph of about 6.3 
   WO03/053399 Pfizer Azithromycin can be produced in many different forms. For 
example, the current commercial from of    Azithromycin is a 
stable, crystalline, non-hygroscopic dihydrate, also referred to as 
from A. The commercial tablet is then formulated by using water 
as the granulating liquid. Several crystalline non-dihydrate forms 
of Azithromycin are also known. From B is hygroscopic crystalline 
hydrate. This form of Azithromycin is difficult to handle during 
formulation due to its propensity for readily absorbing varying 
amount of water. 
  EP01127580 Pfizer  The bioavailability of Azithromycin can be increased by co- 
administering Azithromycin with a p- glycoprotein inhibitor. 
  
  WO03063838 Pfizer    Dry granulated formulations of Azithromycin (using non-dihydrate 
form of Azithromycin ) 
  WO03053416 Pfizer  Directly compressible formulation of Azithromycin (using non 
dihydrate from of Azithromycin) 
 WO2004087096 Pliva Pharmaceutical composition having reduced bitter taste. 
 
EP00679400 
Pfizer The invention provides the use of Azithromycin in the manufacture 
of a rapidly disintegrating oral dosage form with high 
bioavailability for the treatment of a microbial infection in a 
mammal that has eaten or will eat in the period commencing 1 
hour prior to dosing and terminating 2 hour after dosing. 
      
WO200611549
4 
Abraxis 
A stable, sterile liquid formulation comprising lyophilized 
Azithromycin, ethanol, citric acid &/or NaoH. 
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CHAPTER – 5 
Formulation development 
5.1 Objective: 
To develop a non-infringing formulation of Azithromycin, which is stable and 
bioequivalent to Zithromax of Pfizer and being marketed in domestic.  
The strength to be developed is 250 mg.  
 Qualitative composition of the formulation with respect to the Excipients 
would be same as that of the innovator. 
 Quantitative composition would be derived by trials, to ensure a drug product 
having similar physico-chemical properties as that of the innovator.    
Manufacturing Process: 
The same manufacturing process and the equipments used during development 
would be similar to the intended commercial scale equipments. 
5.2 Selection of Excipients 
   Sourcing 
The excipients used during development were procured from qualified 
vendors.  
 5.2.1 Function and Justification
41 
Diluents: In view of drug dose it is essential to add bulking agents or diluents to 
increase the weight of the tablet. Microcrystalline cellulose was selected as the 
main diluent. 
Disintegrant: Cross carmellose sodium we selected as superdisintegrant. The 
strong correlation of disintegration time to bioavailability. Thus, it is important 
to optimize the disintegration time in order to enhance in vivo dissolution of the 
drug. In order to release the active ingredient from a solid dosage form matrix as 
efficiently as possible, disintegrate is often used in the formulation, especially 
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when the dosage forms are compressed with binder. Disintegrates help rupturing 
the dosage form matrix by swelling or capillary action when moisture is 
absorbed into the dosage form.  
  Binder: Pregelatinized starch was used as a tablet binder in the concentration of 
0.5 – 5 %.Formulators skilled in art can determine the binder level for the 
formulations, but binder usage level of 2-25% in tablet formulations is common. 
  Lubricants:  Magnesium Stearate is a widely used as Tablet and Capsule 
lubricant. It is generally used in the concentrations between 0.25 – 5.0 %. 
Glidant: Colloidal Anhydrous Silica is widely used as Tablet and Capsule 
Glidant. It is generally used in the concentrations between 0.25 – 3.0 %. 
Lubricants:  Magnesium Stearate is a widely used in Tablet and Capsule as a 
lubricant. It is generally used in the concentrations between 0.25 – 5.0 %. 
Film former: Hypromellose is widely used in oral and topical pharmaceutical 
formulation. It is generally used in coating suspension in the concentrations 
between 50- 30.0 %. 
Coating agent: titanium dioxide is widely used in oral pharmaceutical 
formulations as white pigment and as opacifier in film coating. it is generally 
used in the concentrations b/w 10.0 – 30.0 %. 
Plasticizer: polyethylene glycol 6000 is widely used as plasticizer in film coating 
of tablet. It is generally used in the concentrations b/w 5.0 – 20.0 %. 
Granulation vehicle: Water is widely used for granulating Agent because of no 
any toxic effect and for non- aqueous solvent we widely use Isopropyl alcohol. 
Wetting agent: Sodium lauryl sulfate is mainly used as wetting agent. It is 
generally used in the concentrations b/w 1.0 – 2.0 %. 
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5.3 Selection of Dissolution Medium 
  Initially dissolution was done with reference product Aazithral in phosphate 
buffer, pH 7.5 in 900 ml with type -2 apparatus at 100 rpm. 
  Later on, it was decided to comply with I.P draft monograph dissolution test 
Dissolution media: sodium phosphate buffer pH 6.0 with trypsin 
Apparatus:  USP II (Paddle) 
RPM:  100 
Time points:  5, 10, 15, 20, 30, 45 minutes 
Identification: HPLC  
Limit:  NLT 75 % labeled amount should release in 45 minutes 
Table no- 6.1 comparative dissolution profile of Azithromycin 250 mg tablets in 
different batches.  
 
Fig – no 2 
 
Batch no 
 
Dissolution media 
Time (min) 
10 15 30 45 
250/015 
Sodium phosphate buffer 
pH 6.0 with trypsin 
59.2 73.7 82.6 95.2% 
250/018 ,, 57.3 74.4 81.7 97.2% 
250/020 ,, 58.5 75.7 82.9 98.1% 
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     Fig –no 2: comparative dissolution profile of Azithromycin 250 mg tablets in 
different batches. 
5.6 Development Trial 
Trial no:-1 prototype formula 
           In the 1
st
 trial we take the excipent as per the innovator.     
      IFF qualitative formulation  
Sr.No Ingredients Function 
1 Pregelatinized starch Binder 
2 Calcium phosphate dibasic Dilunt 
3 Croscarmellose sodium Disintegration 
4 Magnesium Stearate Lubricants 
5 Hypromelose Film former 
6 Lactose Diluent 
7 PEG-6000 Plasticizer 
8 Titanium di oxide Opacifier 
Observation:  Capping is occur 
Remark: API is crystalline, milling required so API is milled by 0.3 mm screen 
and passed in 80 #. 
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Trial no:-2 
             In this trial API is milled through the 0.3 mm screen and passed through 
mesh # 80 
                     
Sr.No Ingredients Function 
1 Pregelatinized starch Binder 
2 Calcium phosphate dibasic Diluent 
3 Croscarmellose sodium Disintegration 
4 Magnesium Stearate Lubricants 
5 Hypromelose Film former 
6 PEG-6000 Plasticizer 
7 Titanium di oxide Opacifier 
 
Observation:  Sticking is occurs  
Remark: Replacement of Dibasic calcium Phosphate  with Microcrystalline 
cellulose  to improve compressibility 
Trial no: - 3 
        In this trial we use microcrystalline cellulose as a diluent and to decrease the 
stickiness  
Sr.No Ingredients Function 
1 Pregelatinized starch Binder 
2 Microcrystalline cellulose Diluent 
3 Croscarmellose sodium Disintegration 
4 Magnesium Stearate Lubricants 
5 Hypromelose Film former 
6 PEG-6000 Plasticizer 
7 Titanium di oxide Opacifier 
 
Observation:  Again we found sticking  
Remark: Add aerosol to reduce the stickiness 
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Trial no: -4  
       In this trial we used Aerosil to reduce the stickiness  
      
Sr.No Ingredients Function 
1 Pregelatinized starch Binder 
2 Microcrystalline cellulose Diluent 
3 Croscarmellose sodium Disintegration 
4 Magnesium Stearate Lubricants 
5 Aerosil Glidant 
6 Hypromelose Film former 
7 PEG-6000 Plasticizer 
8 Titanium di oxide Opacifier 
 
Observation: Improve but DT increased & abrasiveness in blend 
Remark: To solve this problem we Add Sodium lauryl Sulphate to improve 
wettability of API           
Trial no: - 5 
          In this to solve the problem of stickiness we adding Sodium lauryl Sulphate 
Sr.No Ingredients Function 
1 Pregelatinized starch Binder 
2 Microcrystalline cellulose Diluent 
3 Croscarmellose sodium Disintegration 
4 Magnesium Stearate Lubricants 
5 Sodium lauryl Sulphate Wetting agent 
6 Aerosil Glidant 
7 Hypromelose Film former 
8 PEG-6000 Plasticizer 
9 Titanium di oxide Opacifier 
 
Observation: Again slightly sticking occur but DT ok  
Remark: To solve again this problem we adding of Syloid in place of Aerosil. 
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Trial no: - 6 
                   In this trial we used Syloid in place of Aerosil. 
 
Sr.No Ingredients Function 
1 Pregelatinized starch Binder 
2 Microcrystalline cellulose Diluent 
3 Croscarmellose sodium Disintegration 
4 Magnesium Stearate Lubricants 
5 Sodium lauryl Sulphate Wetting agent 
6 Syloid Glidant 
7 Hypromelose Film former 
8 PEG-6000 Plasticizer 
9 Titanium di oxide Opacifier 
Observation: Slightly sticking is occur but at later stage 
Remark: We increased binder addition & kneading time and sizing with 1.2 mm 
in place of 1.00 mm 
Trial no: - 7 
In this trial we increased binder addition time kneading time and sizing 
through 1.2 mm screen    
Sr.No Ingredients Function 
1 Pregelatinized starch Binder 
2 Microcrystalline cellulose Diluent 
3 Croscarmellose sodium Disintegration 
4 Magnesium Stearate Lubricants 
5 Sodium lauryl Sulphate Wetting agent 
6 Syloid Glidant 
7 Hypromelose Film former 
8 PEG-6000 Plasticizer 
9 Titanium di oxide Opacifier 
Observation: No sticking is occurring 
Remark: Finalization of formulation 
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Componenents and composition of the final Formula 
  Strength: 250 mg 
Sr.No Ingredients Function Qty/tablet(m
g) 
% w/w 
1 Azithromycin (as 
dehydrate) 
Active 262.00* 81.88 
2 Microcrystalline 
cellulose 
Diluent 19.06 5.96 
3 Croscarmellose 
sodium 
Disintegrant 2.90 0.91 
4 Pregelatinized starch Binder 12.00 3.75 
5 Sodium lauryl 
Sulphate 
Wetting agent 0.64 0.20 
6 Purified water Granulating 
fluid 
Qs Qs 
7 Syloid 244 FP Glidant 4.80 1.81 
8 Magnesium Stearate Lubricant 4.80 1.50 
9 Hypromelose Film former 6.05 1.89 
10 PEG-6000 Plasticizer 0.85 0.27 
11 Titanium di oxide Opacifier 0.50 0.16 
12 Quinoline yellow Colorant 0.10 0.03 
* 785 mg Azithromycin dehydrate ~ 749 mg Azithromycin anhydrous. 
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6.0 PRODUCT OPTIMIZATION 
          Following parameter were studied with for the optimization of 
manufacturing process and     check robustness of formula. 
6.1 Dispensing: 
           Dispense the all the materials as per robust formula. All material dispense 
under control room temp. 
 6.2 Shifting: 
          Shift the material API through 80 # and other material through 40 # and 60 # 
           There is no residue found on their surface. 
6.3 Dry mixing: 
               Using rapid mixing granulator (capacity – 6 lit.) for dry mixing and 
granulation  
    Dry mixing time optimize with trial of mixing at different time interval. 
 
Conclusion:     
   From the above result, 5 minutes  BUA RSD is very less, so 5 to 8 minutes  
mixing is efficient during dry mixing. Dry mixing at 5 min. gives satisfactory 
result. 
 
Sample no. 3 min. 5 min. 8 min. 
S-1 92.6 99.6 100.5 
S-2 96.3 101.1 98.9 
S-3 95.6 100.4 99.5 
S-4 95.8 98.9 99.35 
S-5 94.2 99.35 99.3 
S-6 91.5 97.8 100.3 
S-7 98.3 99.7 98.9 
S-8 95.4 100.6 100.5 
S-9 96.8 99.8 98.9 
S-10 99.6 99.5 99.3 
Avg. 95.61 99.68 99.55 
SD 2.30 0.88 0.62 
Composite assay (%) 96.5 100.2 99.4 
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6.4 Granulation:  
        Optimization of binder addition time 
     Impeller slow Impeller fast 
1-2 min. 2-3 min. 3-4 min. 5-7 min. 1 min. 2 min 3 min 5 min 
Not good 
wetted and 
no granules 
forms 
Not good wetted 
and no granules 
forms 
Good granules 
are not 
found. 
Uniform 
addition and 
good granule 
Dusting problem during granulation. 
Granules become hard in nature. 
 
The dry mix powder is not bulky, so impeller slow is good for granulation. Binder 
addition with 5 to 7 minutes gives satisfactory result. Chopper will off during 
binder addition to prevent dusting of powder. 
Conclusion:  
            Binder addition time was optimized as 5 to 7 mint with impeller slow and 
chopper off... This gives satisfactory result.  
6.5 Kneading: 
Kneading time – High kneading retard the dissolution due to hard granules 
formed. 
Low kneading produce better result but it is unable to break the lumps and 
produce less uniformity of granulation process. 
        Kneading time High (5-6 mints) Optimum(2-4 
mints) 
Low (1-3 mints) 
Dissolution time in 
minutes 
% drug released 
5 35 45.8 60.8 
10 42.6 56.5 65.8 
15 48.6 60.5 70.4 
20 55.9 65.3 75.3 
30 75.5 78.9 80.5 
45 82.5 88.4 88.5 
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Conclusion: 
            Kneading time was optimized as 2 to 4 mints with impeller fast and 
chopper fast. 
6.6 Drying time 
In granulation process the granulating agent is used purified water. So dry is 
required for remove the amount of water. 
              Set the temp as 60° C for 20 mints and drying up to us got the LOD 
becomes 3 to 4 %. 
6.7 Sizing          
screen size 0.8 mm 1.0 mm 1.2 mm 
Granule 
characteristic 
Passed particle 
are fine and 
high quantity 
of residue 
Low residue 
quantity 
Fine and coarse 
both particles, 
negligible 
residue 
Conclusion: 
Sizing through 1.2 mm screen produce optimum ratio of fine and coarse thus 
sizing through 1.2 mm screen gives satisfactory result.  
 
6.8 Blending  
         Blending time is optimized with trial at different period of blending.  
    Sample no. 5 min. 8 min. 10 min. 12 min. 
S-1 90.30 92.40 95.13 97.32 
S-2 91.33 97.72 94.50 98.52 
S-3 88.91 94.45 96.17 94.65 
S-4 87.92 97.58 96.48 97.57 
S-5 78.36 96.26 96.76 97.41 
S-6 89.04 95.54 96.00 96.98 
S-7 92.33 95.14 96.34 96.00 
S-8 97.62 96.15 96.42 94.53 
S-9 92.58 95.31 96.79 96.35 
S-10 95.71 97.34 96.40 96.80 
Avg 90.41 95.79 96.10 96.71 
SD 5.22 1.69 0.76 0.80 
Composite 
assay 
94.80 97.00 95.62 96.05 
        Conclusion: 10 minutes gives low SD value and good assay result.     
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6.9 Lubrication: 
        Lubrication time is optimizing with trial at different period of mixing.  
         RPM was set as 10 to 20. 
Sample no. 3 mints 5 mints 7mints 
L – 1 95.2 99.2 98.6 
L – 2 91.1 99.4 94.6 
L – 3 95.5 97.5 97.5 
L – 4 96.2 98.8 99.8 
L – 5 98.7 100.2 99.4 
L – 6 99.4 99.1 100.1 
L – 7 94.3 98.3 99.7 
L – 8 95.3 98.9 96.4 
L – 9 98.3 99.7 99.2 
L – 10 99.5 99.9 98.7 
Avg 96.35 99.1 98.4 
SD 2.52 0.75 1.66 
Composite Assay 96.4 100.1 98.6 
Conclusion: ok  
6.10 Tablet compression:  
Selection of punch and die 
Compress the granules into tablets on rotary compression machine using 12/32"                      
     SC, Plain/Plain (D tooling) punches plain on both the sides. 
Parameters set up: 
1. Set up of tablet weight and marketing requirements we are selecting punch 
and die. This tablet weight is 312.00 mg ± 3 %. 
  2. Set up of hardness  
       Effect of hardness on friability: 
Sample Hardness range 
(N) 
Friability Dissolution (%) in 45 
minutes 
1 50 – 90 0.39 88.6 
2 90 – 130 0.15 89.7 
3 130 – 170 0.09 78.5 
Conclusion: 
  We set various hardness 50 to 200 N  
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Product Composition:  
6.11 Demo Batch: 
6.11.1 Product Composition:  
            Strength: 250 mg 
  Lot A: Granulation  
S. 
No. 
Ingredients Spec. Function %w/w 
Qty Tab. 
(In mg) 
Qty./ 
Batch (g) 
 Dry mix: 
1 
Azithromycin  
(as dihydrate) 
USP Active 81.88 262.00 1572.00
$
 
2 
Microcrystallin
e cellulose 
IP Diluent 5.96 19.06 114.36
$
 
3 
Croscarmellose 
Sodium 
USP/
NF 
Disintegrant 0.91 2.90 17.40 
4 
Pregelatinized 
Starch 
USP Binder 3.75 12.00 72.00 
 Granulation : 
5 
Sodium Lauryl 
Sulphate 
IP 
Wetting 
agent 
0.20 0.64 3.84 
6 Purified water 
USP/EP
/BP/IP/ 
IH 
Granulating 
fluid 
Qs Qs 600.00 
 Dried sized granules weight   296.60 1779.60 
Lot B: Granulation 
S. 
No 
Ingredients Spec. Function %w/w 
Qty Tab. 
(In mg) 
Qty./ 
Batch (g) 
 Dry mix: 
  1 
Azithromycin  
(as dihydrate) 
USP Active 81.88 262.00 1572.00
$
 
2 
Microcrystalline 
cellulose 
IP Diluent 5.96 19.06 114.36
$
 
3 
Croscarmellose 
Sodium 
USP/
NF 
Disintegrant 0.91 2.90 17.40 
4 
Pregelatinized 
Starch 
USP Binder 3.75 12.00 72.00 
 Granulation : 
5 
Sodium Lauryl 
Sulphate 
IP Wetting agent 0.20 0.64 3.84 
6 Purified water 
USP/EP
BP/IP/ 
IH 
Granulating 
fluid 
Qs Qs 600.00 
 Dried sized granules weight   296.60 1779.60 
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 Blending of Lot A and Lot B : 296.60 3559.20 
 Lubrication : 
7 Croscarmellose Sodium 
USP
/NF 
1.50 5.80 69.60 
8 
Silicon Dioxide 
(Syloid  244 FP) 
USP
-NF 
1.81 4.80 57.60 
9 Magnesium Stearate IP 1.50 4.80 57.60 
 Core tablet  weight 97.50 312.00 3744.00 
 Coating Ingredients@ : 
10 Hydroxyl Propyl Methyl 
Cellulose (6cps) 
IP 1.89 6.05 116.16 
11 PEG -6000 IP 0.27 0.85 16.32 
12 Talc IP 0.16 0.50 9.60 
13 Titanium dioxide IP 0.16 0.50 9.60 
14 Quinoline yellow IH 0.03 0.10 1.92 
15 Purified water 
USP
/EP
BP/I
P/ 
IH 
Qs Qs 1382.0 
 Coated tablet weight 100.00 320.00 3840.00 
  
Note:
   
$
  Quantity of Azithromycin (as dihydrate) USP taken considering 100% assay      
on as such basis, its quantity to be adjusted with Microcrystalline cellulose IP. 
        @ 60 % extra coating solution to be prepared to compensate loss during coating 
262.00 mg of Azithromycin USP (as dihydrate) equivalent to 250.00 mg 
Azithromycin  anhydrous. 
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6.11.2 Formula Calculation:  
For each Lot: 
Qty of Azithromycin dihydrate USP 
                                  Required (Q) =            1500.00 x 100 x 100      gm                     
                                                                                  A x (100 – W)                                                                                                            
    Where A= Assay of Azithromycin dihydrate on anhydrous basis in %. 
               W= water by K.F. in % w/w                                                           
         Quantity of Microcrystalline cellulose IP required:  
   =   114.36gm – (Q – 1572.00) gm 
Remark: Record B. No., Assay (anhydrous basis) & water by K.F. of API used. 
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6.11.3 Process Flow Diagram-Schematic: 
Ingredients               Process step / equipment                  In-process Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
  
 
 
 
 
 
                  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
Azithromycin 
Dihydrate 
Milling  
(Comminuting Mill, 0.3mm impact 
forward, fast speed) 
Co-sifting 
Mechanical Sifter 
(40#) 
 
 
 
Granulation (RMG) 
Binder addition time: 7 to 8 minute. Impeller: slow, 
Chopper: off. Kneading time: 5 to 7 minute 
 Impeller: fast, chopper: fast 
 
 
 
Drying (FBD) 
Temp: 60°C ± 5°C 
 
Sizing (1.2 mm OG) 
 
 
 
Purified Water + SLS 
Through Peristaltic pump 
Blending 
Conta Blender 10 min. 17 rpm 
 
 
 
Compression 
 
 
 
 
Croscarmellose Sodium, 
Silicon dioxide 
Co-sifting  40 #  
 
Coating (Autocoater) 
 
 
 
 
 
 
HPMC E6 
PEG 6000 
Talc 
Titanium Dioxide 
Lake of Quinoline Yellow 
Purified Water 
Filter through 100 #  
 
 
Packing  
(Transparent yellow PVC/Alu Blister) 
 
 
 
Sifting 
Mechanical Sifter 
(80#) 
 
 
 
Dry Mixing (RMG) 
Time: 5 minute, Impeller: slow, 
chopper: off 
 
 
 
Lubrication  
Conta Blender 6 lit, 5 min. 17 rpm 
 
 
 
 
Magnesium Stearate 
 60 # 
 
Wet milling (8 # mesh) 
 
 
 
Dry mix B.D: 0.40 gm/cc  
LOD: 3-4% at 105°C 
 
 
Description, Wt of 20 
tabs Uniformity Wt, 
Assay, Hardness, 
Thickness, Friability, and 
DT 
 
 
 
Description, % Wt gain,  
Thickness, Avg. wt, DT, 
Water content (by K.F.) 
 
 
 
 
 
 
Description, Assay, BUA, 
B.D, T.D., C.I, AOR, Flow rate 
(gm/min) Sieve analysis 
 
LOD@105°C: 3-4% 
 
 
As per Finished Product 
Release Specifications 
 
 
 
 
 
 
LOD@105°C 
 
 
Microcrystalline Cellulose  
Croscarmellose Sodium 
Pre gelatinized starch 
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6.11.13 complete analysis of core tablets: 
 
 
 
Sr.No Test Limit 
250 mg 
 
1 Description White,round,biconvex tablet, plain on both side 
2 Average weight 312.0±3% 312.00 
3 
Assay 
Optimum Hardness 
 
115 N ± 20 N 
 
100.0 % 
4 
Related Substances 
(Optimum Hardness) 
Single Max impurity 
Total impurities 
To be monitored 
 
 
0.74% 
1.78% 
5. 
Dissolution  (45 min) 
 
pH 6.0,phosphate buffer,600 mg trypsin added,900 
ml/paddle/100 rpm/time point:45 min 
 
 
Optimum Hardness 
Low Hardness 
High Hardness 
 
NLT 75%(D) 
 
98.4 (2.68) 
92.3 (1.5) 
99.5 (1.49) 
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6.11.14 complete analysis of coated tablets: 
 
 
 
 
 
 
 
Sr.N
o 
Test Limit  250 mg 
1 Description  yellow,round,biconvex tablet, plain on both 
side 
2 Average weight 320.0±3% 320.00 
3 Assay  
optimum hardness 
 
----  
98.7 % 
4 Related Substances 
(optimum hardness) 
Single Max impurity  
Total impurities 
To be 
monitored 
 
 
0.94% 
1.89% 
5. Dissolution  pH 6.0,phosphate buffer,600 mg trypsin 
added,900 ml/paddle/100 rpm/time point:45 
min 
6 % Drug Release  
  (45 min) 
optimum hardness 
(RSD) 
 
NLT 75%(D) 
 
99.8  (1.43) 
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6.11.15 Conclusion/Recommendation 
1. Water addition rate should be control with peristaltic pump with in binder 
addition time period as   Mentioned. 
2. Granulation should be perform with slow addition of binder solution and 
kneading with impeller slow & chopper off to get desired granule characteristics. 
2. Wet milling should be performed after granulation. 
3. Drying should not perform at more than 55±5°C temp. 
4. During coating product temp should not be more than 40°C± 5°C 
6.11.16 Stability study  
             Demo Batch  
Batch No – Demo batch                 Packing – Yellow PVC blister 
B. Size – 12000 tablet 
 
    Storage condition 
 
        40 °C, 75 % RH 
Sr. 
No 
Tests Specification Initial 1 month 2 month 
1 Description Yellow colored, round 
shaped, biconvex, 
coated tablet, plain on 
both side. 
complies Complies complies 
2 Assay (%) 90 % to 110 % of 
label claim 
99.7 99.2 100.1 
3 Water 
content (%) 
To record 5.12 5.32 5.40 
4 Disintegrati
on time 
Not more than 30 
minutes 
1.56 1.30 2.45 
5 Dissolution 
at pH 6.0 
phosphate 
buffer 
Not less than 75 % (D) 
in 45 minutes 
95.2 
(0.58) 
99.4 9 
(0.85) 
100.6 
(2.08) 
Observation: Stability data show that drug product is stable upto 2 month in 
accelerated condition  
 
 
 Chapter 6                                                                  PRODUCT OPTIMIZATION 
 
Dept. of Pharmaceutics 85 JKK Nattraja College of Pharmacy 
 
 
 
 
Observation: Stability data show that drug product is stable upto 2 month in 
intermediate condition. 
 
 
 
 
 
 
 
Batch No – Demo batch                 Packing – Yellow PVC blister 
B. Size – 12000 tablet 
 
    Storage condition 
 
        30 °C,  75 % RH 
S.
No 
Tests Specification Initial 1 month 2 month 
1 Description Yellow colored, round 
shaped, biconvex, 
coated tablet, plain on 
both side. 
complies Complies complies 
2 Assay (%) 90 % to 110 % of 
label claim 
99.7 99.5 98.8 
3 Water 
content (%) 
To record 5.12 5.42 5.6 
4 Disintegratio
n time 
Not more than 30 
minutes 
1.56 2.00 2.00 
5 Dissolution 
at pH 6.0 
phosphate 
buffer 
Not less than 75 % 
(D) in 45 minutes 
95.2(0.58
) 
97.6 97.5 
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Batch No – Demo batch                Packing – Yellow PVC blister 
B. Size – 12000 tablet 
    Storage condition 
 
        25°C,  60 % RH 
S.
No 
Tests Specification Initial 1 month 2 month 
1 Description Yellow colored, round 
shaped, biconvex, 
coated tablet, plain on 
both side. 
complie
s 
Complie
s 
complies 
 
2 Assay (%) 90 % to 110 % of 
label claim 
99.7 99.9 100.0 
3 Water content 
(%) 
To record 5.12 5.28 5.30 
4 Disintegration 
time 
Not more than 30 
minutes 
1.56 2.00 2.10 
5 Dissolution at 
pH 6.0 
phosphate 
buffer 
Not less than 75 % 
(D) in 45 minutes 
95.2(0.5
8) 
96 97.23 
 
 
Observation: Stability data show that drug product is stable upto 2 month in 
normal condition  
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6.11.4 Processing steps:  
Process Stage 
Critical Process 
Parameter 
Expected 
Response 
Observed 
Response 
Remarks Proposed Specifications 
Lot A granulation 
API milling 
0.3 mm screen, impact 
forward, fast speed in 
cad mill 
0.3 mm screen, impact 
forward, fast speed in 
cad mill 
0.3 mm screen, impact 
forward, fast speed in 
cad mill 
Satisfactory 
0.3 mm screen, impact forward, 
fast speed in cad mill 
Granulation 
 
1.Binder Addition 
Time(Peristaltic pump 
rate) 
2.Kneading Time 
6-8 Minutes 
5 to 7 Minutes 
(fast-fast) 
4 min 30 sec 
7 min (impeller slow, 
chopper off) 
Satisfactory 
(Kneading parameter have 
to changed to get  desire 
granules consistency) 
6-8 Minutes 
5 to 7 min (impeller slow, 
chopper off) 
Wet milling 8 #  sieve 8 # sieve 8 #  sieve Satisfactory 12.7 mm Co- mill 
Drying LOD@105°C 3.0% to 4.0% 4.56% Dry mix LOD was 5.0% 3.5% to  5.0% 
Sizing 
1.2 mm screen on 
horizontal  O.G. 
1.2 mm screen on 
horizontal O.G. 
1.2 mm screen on 
horizontal O.G., 
Satisfactory 1.2 mm screen on horizontal O.G. 
Lot B granulation 
Granulation 
 
1.Binder Addition 
Time(Peristaltic pump 
rate) 
2.Kneading Time 
6-8 Minutes 
 
5 to 7 Minutes 
7 min 
(30 ml/min) 
7 min 
Satisfactory 
6-8 Minutes 
5 to 7 min (impeller slow, 
chopper off) 
Wet milling 8 #  sieve 8 # sieve 8 #  sieve Satisfactory 12.7 mm Co- mill 
Drying LOD@105°C 3.0% to 4.0% 4.62 % Dry mix LOD was 4.68 % 3.5% to  5.0% 
Sizing 
1.2 mm screen on 
horizontal O.G. 
1.2 mm screen on 
horizontal O.G. 
1.2 mm screen on 
horizontal O.G. 
Satisfactory 1.2 mm screen on horizontal O.G. 
Blending of Lot A & B 10 min. 10 minutes 10 minutes Satisfactory 10 minutes 
      
Blending 10 min. 10 minutes 10 minutes Satisfactory 10 minutes 
Lubrication 5 min. 5 min. 5 min. Satisfactory 5 min. 
Granulometry 
Bulk Density 
Tapped Density 
Sieve Analysis 
To be recorded 
To be recorded 
To be recorded 
0.47 
0.58 
 
Satisfactory 
Satisfactory 
Satisfactory 
To be recorded 
To be recorded 
To be recorded 
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Compression : For 250 mg strength: 
Avg weight 312.00 ± 3% 312.16  mg Satisfactory 312.00 ± 3% 
Thickness 5.00 ± 0.3 mm 5.10 mm Satisfactory 5.00 ± 0.3 mm 
Hardness (115±20 N ) 125 N Satisfactory (115±20 N ) 
Friability NMT 1.0% 0.1 % Satisfactory NMT 1.0% 
D.T. NMT 15 min 1 min 23 sec Satisfactory NMT 15 min 
Coating : For 250 mg strength: 
Inlet temp 60 ± 5° C 60 ± 5° C Satisfactory 55 ± 5 °C 
Product temp 45 ± 5 °C 40 ± 5 °C Satisfactory 40 ± 5 °C 
Pan RPM 2-4 2-4 Satisfactory 2-4 
 
6.11.5 Ingredients and sieve used: 
Sr. No. Ingredients Code Screen Size Remarks 
1 Azithromycin dehydrate 1000494 80# Satisfactory 
2 
Microcrystalline 
cellulose 2000185 
40# Satisfactory 
3 Pregelatinized starch 2000227 40# Satisfactory 
4 Croscarmellose sodium 2000054 40# Satisfactory 
5 Silicon dioxide 2000446 40# Satisfactory 
6 Magnesium Stearate 2000156 60# Satisfactory 
 The above API was co-sifted with dry mix excipients sifted on vibratory sifter. 
Description: White to off-white granular powder. 
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6.11.6 Dry mix blends analysis: 
 
Sr.
No. 
Parameter Results 
1 Dry mix  : Time 5 minutes 
2 B.D. 0.41 gm/cc 
3 LOD AT 105°C 4.68% 
 
6.11.7 Details of the blend characteristics after sizing: 
 
Sr. No Parameter Lot A Lot B 
1 Description 
White to off-white 
granular powder 
White to off-white granular 
powder 
2 B.D 0.47 gm/cc 0.46 gm/cc 
3 T.D 0.57 gm/cc 0.55 gm/cc 
4 C.I 17.39 14.66 
5 H.R. 1.23 1.19 
6 AOR 24.3° 23.7° 
7 
Flow rate (Erveka flow meter, 
15.0 mm funnel) 
10.6 sec/100 gm 9.8 sec/100 gm 
8 Particle size distribution % wt retain % wt retain 
 #20 retain 1.44 3.52 
 #20-#30 7.9 5.34 
 #30-#40 8.32 12.06 
 #40-#60 18.56 16.42 
 #60-#80 19.58 19.68 
 #80-#100 16.34 16.20 
 Pass through # 100 27.32 24.20 
9 Assay 96.7 % 98.2 % 
10 
Related Impurities 
Single Max Impurity 
Total Impurities 
 
0.83 % 
1.88 % 
 
0.72 % 
1.95 % 
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6.11.8 Details of the lubrication: 
Blending with Croscarmellose sodium & Silicon Dioxide: 10 minutes 
Lubrication with Magnesium stearate: 5 minutes in conta blender at 17 rpm           
Inference: 10 min with Croscarmellose sodium & Silicon Dioxide then 5 min 
with Magnesium stearate is sufficient. 
6.11.9 Final blend characteristics: 
Sr.
No. 
Parameter Results 
1 Description White to off-white coloured 
granular powder 
2 LOD@105°C 4.78% 
3 Bulk  density 0.49 gm/cc 
4 Tapped density 0.62 gm/cc 
5 Hausner’s ratio 1.27 
6 Compressibility Index 21.37% 
7 Angle of repose 24.8° 
8 Flow rate (Erveka flow 
meter, 15.0 mm funnel) 
8.5 sec/100 gm 
9 Particle size distribution % Retain 
 #20 retain 2.6 
 #20-#40 18.1 
 #40-#60 17.45 
 #60-#80 17.10 
 #80-#100 11.70 
 Pass through # 100 33.00 
10 Blend uniformity  
 S-1 98.4 
 S-2 97.5 
 S-3 98.9 
 S-4 97.2 
 S-5 99.4 
 S-6 98.8 
 S-7 97.8 
 MEAN 98.3 
11 Composite 101.8 
12 Related Impurities 
Single Max Impurity 
Total Impurities 
0.52% 
0.52% 
Inference: Lubricated blend is found satisfactory in terms of flow and particle size 
distribution 
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6.11.10 compressions: 
S.No. Parameters Observation 
  250 mg 
01 
Machine Name Cad mach rotary compression machine 20 
station 
02 Machine rpm 25 
03 
Punch description 
 
  
12/32" Circular Biconvex, Plain/Plain (D 
tooling) punches plain on both the sides. 
04 No. of punch sets 2 sets 
05 Machine run time  3 hr 
6.11.11 Compression parameters: 
Batch no. 
 
Demo 
Dimension 12/32" 
U/P plain 
L/P plain 
Tooling D 
Low hardness 
Average weight (mg)                                                                                                     
312.0 ± 3 %                                  
(302.64 to 321.36 mg) 
311.39mg                                                 
(308.0 mg to 314.0 mg) 
Optimum hardness 
312.16mg                                                 
(311.6 mg to 313.0 mg) 
High hardness 
308.2mg                                                 
(306.8 mg to 309.5mg) 
Low hardness 
Hardness 
115 N ± 20 N                                     
(95 N to 135 N) 
63.70N                                                          
(61 N to 75 N) 
Optimum hardness 
125.10N                                                          
(113 N to 140 N) 
High hardness 
165.60N                                                          
(138 N to 182 N) 
Low hardness 
Thickness 
5.00 ± 0.3 mm                           
(4.70  to 5.30 mm) 
5.29mm                                             
(5.21 mm to 5.39 mm) 
Optimum hardness0 
5.10mm                                             
(4.96 mm to 5.31 mm) 
High hardness 
4.82mm                                             
(4.78 mm to 4.87 mm) 
Low hardness 
DT                                             
NMT 15 mins. 
54 sec 
Optimum hardness 1.0 min 40 sec 
High hardness 3.0 min 10 sec 
Low hardness 
Friability  %w/w                                            
NMT 1.0 % w/w 
100R-0.28  200R–0.39%                                     
300 R - 0.46 % 
Optimum hardness 
100R-0.1% 200R-0.27%                                      
300 R - 0.37 % 
High hardness 
100R-0.20% 200R-0.26%                                      
300 R - 0.41 % 
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6.11.12 Coating parameters: 250 mg 
 
 
 
 
 
 
 
 
Time Inlet Temp 
 
Product temp Pan rpm Spray rpm Spray rate 
12:05 56 40 1 - - 
12:15 57 40 1 - - 
12:17 57 38 2 2 3 
12:25 62 39 3 3 5 
12:30 60 39 3 3 6 
12:40 67 39 3 4 6 
12:45 66 40 3 5 6 
12:55 66 38 3 3 6 
13:05 63 37 3 3 5 
13:15 64 37 3 3 5 
13:25 45 35 2 - - 
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Product Composition:  
Granulation lot A & Lot B 
S. 
No 
Item code Ingredients 
Spec. 
* 
Functi
on 
%w/
w 
Qty 
/Tab. 
(In 
mg) 
Qty./ba
tch 
(In kg) 
 Dry mix: 
  1 1000494 
Azithromycin  
(as dihydrate) 
USP Active 
81.8
8 
262.0
0 
19.65
$
 
2 1000494 
Azithromycin  
(as dihydrate) 
USP Active -- -- 0.20# 
3 2000185 
Microcrystalline 
cellulose 
IP 
Diluen
t 
5.96 19.06 1.43
$
 
4 2000054 
Croscarmellose 
Sodium 
USP/
NF 
Disint
egrant 
0.91 2.90 0.218 
5 2000227 
Pregelatinized 
Starch 
USP Binder 3.75 12.00 0.900 
 Granulation : 
6 2000329 
Sodium Lauryl 
Sulphate 
IP 
Wettin
g 
agent 
0.20 0.64 0.048 
7 1822352 Purified water 
USP/P
h.Eur/
BP/ 
IP/IH 
Granul
ating 
fluid 
Qs Qs 
7.500*
* 
 Dried sized granules weight   296.60 22.246 
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S. 
No 
Item 
code 
Ingredients 
Spec
.* 
%w/
w 
Qty 
/Tab. 
(In mg) 
Qty./batch 
(In kg) 
 Blending of Lot A and Lot B : 296.60 44.492 
 Lubrication : 
8 2000054 
Croscarmellose 
Sodium 
USP
/NF 
1.81 5.80 0.870 
9 2000446 
Silicon Dioxide 
(Syloid  244 
FP) 
USP
-NF 
1.50 4.80 0.720 
10 2000156 
Magnesium 
Stearate 
IP 1.50 4.80 0.720 
                                             Core tablet  
weight 
97.5
0 
312.00 46.802 
Coating Ingredients@ : 
11 
2000115 
Hydroxyl 
Propyl Methyl 
Cellulose (6cps) 
IP 1.89 6.05 1.452 
12 2000198 PEG -6000 IP 0.27 0.85 0.204 
13 2000352 Talc IP 0.16 0.50 0.120 
14 
2000358 
Titanium 
dioxide 
IP 
0.16 0.50 
0.120 
15 
2000241 
Quinoline 
yellow 
IH 
0.03 0.10 
0.024 
16 1822352 Purified water 
USP/P
h. 
Eur/B
P/IP/ 
IH 
Qs Qs 17.280** 
                                 Coated tablet weight 100.00 320.00 48.000 
Note:
  
 *   Always current version of specification should be followed 
  $   
 Quantity of Azithromycin (as dihydrate) USP taken considering 100% assay on                  
As such basis, its quantity to be adjusted with microcrystalline cellulose IP 
     #   1.0% w/w extra API to be dispensed to compensate for milling loss and 19.65 kg                
milled API with assay compensation is to be used for the further processing. The 
excess API, if Any, is to be discarded after milling. 
 @   60 % extra coating solution to be prepared to compensate loss during coating 
**    Removed during process, does not remain in the finished product 
    
262.00 mg of Azithromycin USP (as dihydrate) equivalent to 250.00 mg 
Azithromycin Anhydrous. 
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 Formula Calculation:  
7.1 Calculation for actual quantity of Azithromycin dihydrate USP: 
For each Lot:  
Actual Quantity of      
Azithromycin 
dihydrate USP                                  
Required in kg (Q) 
per batch 
=
  
Assay on anhydrous basis            Assay on as is basis 
 
18.75 x 100 x 100                 or                18.75 x 100 
A x (100 – W)                                                 B 
Where: 
 
A = Assay of Azithromycin USP on anhydrous basis in % w/w 
 
B = Assay of Azithromycin USP on as is basis in %w/w 
 W= water by KF in % w/w  
7.2 Calculation for actual quantity of microcrystalline cellulose IP 
(Depending upon 3.1.1 and Theoretical Quantity of Microcrystalline cellulose IP) 
 
Actual Quantity of  Microcrystalline 
cellulose IP required per batch in kg (P) 
=  1.43 – ( Q – 19.65) 
    
 Note:  
API of multiple A.R. No’s may be used for which assay calculation has to be 
done  accordingly         
 
  
 
 
 
 
  
 Process Flow Diagram-Schematic: 
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7.3 Manufacturing conditions and Precautions: 
 Ensure that all the area is cleaned and free from previous product material before taking 
any batch 
 Ensure that all the input materials used in a batch bear QA approved labels. 
 Ensure that all the personals in the manufacturing area wear protective clothing.  
 Ensure that the Room Temperature is NMT 27°C and Relative humidity is below 60 % 
RH. 
Ensure that all the activities are carried out as per MFC and recorded in the BMR.   
7.3.1 Manufacturing Process: 
7.3.2 Milling of API: Mill the Azithromycin dihydrate USP through 0.3mm screen impact 
Forward at fast speed in Cadmill. 
7.3.3 Dispensing:  
Check all the dispensed ingredients as per the material requisition note and record in 
BMR.      
7.3.4 Sifting      
1 Sift the calculated quantity of milled API through 80 # mesh on Vibratory sifter. 
2 Co-sift the calculated quantity of Microcrystalline cellulose IP, Croscarmellose sodium    
USP-NF 0.218 kg and Pregelatinized starch USP 0.900 kg with API of step 7.3.1 through 
40# on vibratory sifter 
 
 
 
 
 
 
 
 
 
7.3.5   Dry Mixing                
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      Load the sifted materials from step 9.4.3 into a clean and dry Rapid Mixer 
Granulator fitted with co-mill having 8.0 mm SS Screen and mix for 5 minutes 
with Chopper off and impeller at slow speed.             
 
          Sampling locations in Rapid mixer Granulator:                               
                            X  Y   Z             
Figure No. 8.1: Sampling locations in Rapid mixer Granulator (Not to scale) 
 
X – 1/3 of material height from bottom – Top layer 
                                                                                                               
Y – 1/2 of material height from bottom – Middle layer 
 
 Z – 2/3 of material height from bottom – Bottom layer 
S1 –Upper –Rear S6 – Middle– Center 
S2 - Upper –Left  S7-Lower – Rear 
  S3 – Upper – 
Center 
S8 – Lower – Left 
S4 – Upper - Right S9 – Lower – Right 
S5 – Upper- Front S10 – Lower – Front 
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7.3.6 Granulation  
       1) Binder solution preparation 
            Dissolve Sodium Lauryl Sulphate IP 0.048 kg in 7.500 kg of purified 
water USP/Ph. 
          Eur/BP/IP/IH to get a clear solution. 
2) Binder Solution Additions 
          Add binder solution prepared at step 7.5.1 to the dry mixed of step 7.4 
by using peristaltic  
          Pump in Rapid Mixer Granulator fitted with co-mill having 8.0 mm SS 
Screen with  
          Impeller at slow speed and Chopper off in 6 to 8 min. 
3) Kneading 
 
          Carry out kneading for 4 to 7 minutes at impeller slow and chopper off.  
If required, add  
          Extra amount of Purified water USP/Ph.Eur/BP/IP/IH to get the desired 
consistency of wet       
          Mass.  Record the extra quantity added in BMR.Unload the wet mass 
(Granules) through  
          Co-mill using 8.0 mm SS Screen. 
7.3.7 Drying 
 Dry the wet mass of Step of 7.5.3 at inlet air temperature 55 ± 5°C 
to get LOD 3.5% to  
       5.0% w/w at 105°C.      
7.3.8 Sizing: 
 Pass the dried granules of step 7.6 through Oscillating granulator fitted 
with 1.2 mm SS  
      Screen. Collect the granules into clean & dry suitable container.        
                                   Theoretical Yield =   22.246 kg 
Lot B: Granulation 
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   Manufacturing Process: for Lot B: Granulation 
      Repeat the manufacturing process same as steps 9.1 to 9.7 
7.3.9 Blending I of Lot A and Lot B: 
        Blending the Lot A and Lot B sized granules in Bunker with Conta blender 
for 10 min. 
7.4 Blending – II:   
7.4.1 Sift 0.870 kg of Croscarmellose sodium USP/NF and 0.720 kg Silicon 
Dioxide USP-NF  (Syloid 244 FP) through 40# sieve on vibratory sifter.  
7.4.2 Blend the granules of step 7.8 with Croscarmellose sodium USP/NF and 
Silicon Dioxide (Syloid 244 FP) USP-NF for 10 minutes in Bunker with Conta 
blender. 
7.5 Lubrication: 
7.5.1 Sift 0.720 kg of Magnesium Stearate IP through 60# sieves on vibratory 
sifter then blend  With material of step 7.9.2 for 5 minutes 
7.5.2 Send the sample of blend material to Q.C along with sample test request 
slip for  Analysis. 
 
7.5.3 Weight and record the yield of the blend in BMR. 
                             Theoretical Yield: 46.802 kg       
 
 
 
 
 
 
 
 
 
Sampling Instruction: 
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Insert the unit dose sampler at an angle of 45-60
0
 in closed position, such that the 
slot is facing upwards at the nearest locations identified in the figure. 
Figure No. 7.2: Sampling locations in Conta Blender (Not to scale)  
 
 
 
 
 
 
 
   
    
   
 
                  Bunker  
 
X – 2/3 of material height from bottom – Upper layer 
Y – 1/2 of material height from bottom – Middle layer 
  Z -- 1/3 of material height from bottom – Lower layer 
 
 
 
 
 
 
 
7.6   Compression:   
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7.6.1.  Conmpress the granules into tabalets on rotary compression machine 
using 12/32” SC, plain /Plain (D tooling ) punches plain on both sides 
7.6.2 Check Description, Weight of 20 tablets, Average weight, Uniformity of 
weight Hardness, Friability, Thickness, Disintegration time & record these 
parameters in BMR. 
7.6.3. Send the sample of compressed tablets to QC along with sample test 
request slip for analysis Weigh and record the weight of compressed tablets in 
BMR. 
 
                                       Theoretical yield = 46.802 kg 
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7.7 Coating 
Preparation of Film coating suspension: 
7.7.1 Take 10.00 kg Purified Water USP/Ph.Eur/BP/IP/IH in a SS tank and 
slowly add 1.452 kg  Hydroxyl Propyl Methyl Cellu. (6cps) IP into it while 
stirring. Stir continuously till Clear Solution is obtained.  
7.7.2 Take 5.00 kg of Purified Water USP/Ph.Eur/BP/IP/IH. Disperse 0.120 kg 
Titanium Dioxide IP and 0.120 kg Talc IP and 0.024 kg of Quinoline yellow IH 
mill it in colloidal Mill for 20 min.  Rinse the colloid mill with Purified water 
USP/Ph.Eur/BP/IP/IH 
7.7.3 Add suspension of step 7.12.2 in solution of step 7.12.1 with continuous 
stirring. 
7.7.4 Dissolve 0.204 kg PEG 6000 IP in purified water USP/Ph.Eur/BP/IP/IH 
and add in to Coating suspension of step 7.12.3. Continue the stirring for 10 
minutes. 
7.7.5 Filter the coating solution through 100#. 
 
 
 
 
 
 
 
 
 
 
7.7.6 Drying/Heating of Tablets 
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Stage Inlet Temp. 
(°C) 
Duration 
(min) 
Pan RPM 
Before Coating 55 ± 5 10 Inching 
After 100% 
Coating 
40 ± 5 10 Inching 
7.7.5 Coating parameters: 
 
Sr. 
No. 
Parameter Limit 
01. Inlet air temperature 55.0 °C ± 5.0°C 
02. Exhaust temperature To be established 
03. Pan R.P.M. To be established 
04. Spray rate To be established 
05. Atomization air 
pressure 
To be established 
06. Product temperature 40 ± 5°C 
07. Spraying gun nozzle 
Diameter 
1.2 mm 
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7.8 Coating Process: 
 7.8.1 Prior to loading the tablets in coating pan, record average mass (A) of 50 
tablets. 
  7.8.2 Spray the coating suspension on the tablets in pan according to conditions 
given above till required weight gain is achieved. After completion of coating 
process, allow the tablets to dry in the pan in inching mode for 10 minutes in a 
stream of air temperature at 40°C ±5°C.  
7.8.3 Record the average mass of coated tablets in the BMR. Weight gain should 
be 2.5 + 0.5% w/w on the average mass (A). 
7.8.4 Unload the coated tablets in to a clean double polypropylene lined 
container. Weigh and record the weight of coated tablets in BMR.  
7.8.5 Send the sample of coated tablets along with Test Request Form to QC 
dept.for analysis as per finish product release specification. 
 
                                       Theoretical yield = 48.000 kg 
7.8.6 On receipt of QA/QC approval, send the tablets for packing. 
 
 
 
 
 
 
 
 
 
 Chapter 7                                                                                Materials and Methods 
 
Dept. of Pharmaceutics                        100                 JKK Nattraja College of Pharmacy 
 
 
 
7.9. In process test parameters: 
Stage Test Acceptance Criteria 
Drying LOD 3.5 – 5.0 %w/w at 105°C 
Lubrication 
Description White to off-white granular powder 
Water Content NMT 6.0%w/w 
Assay 
Not less than 95.0 % and not more than 
105.0% of labeled amount of Azithromycin. 
Compression 
Description 
White to off-white, round biconvex, uncoated 
tablets plain on both sides 
Average weight 312.0 mg + 3% (302.6 mg to 321.3 mg) 
Weight of 20 tablets 6.24 g + 3% (6.05g to 6.43 g) 
Uniformity of weight Average weight + 5 % 
Hardness 115 N ± 40 N (75 N to 155 N) 
Disintegration time Not more than 15 min 
Friability Not more than 1% w/w 
Thickness 5.00  ± 0.30 mm (4.70 mm to 5.30 mm) 
Dissolution 
Not less than 75 % (D) of the labeled 
amounts of Azithromycin dissolved in 45 
minutes. 
Assay 
Not less than 95.0% and not more than 
105.0% of the labeled amounts of 
Azithromycin 
Water content NMT 6.0%w/w 
Coating* 
Description 
Yellow colored, round biconvex, film coated 
tablets plain on both sides 
Thickness 5.10 ± 0.30 mm (4.80 mm to 5.40 mm) 
Theoretical weight 320.0 mg 
Avg. Weight 320.0 mg ± 3 % (310.4 mg to 329.6 mg) 
% Wt. gain 2.50% ± 0.5% 
Disintegration Time Not more than 30 min. 
Uniformity of Weight 
Not more than two of the individual weights 
deviates from the average weight by more 
than 5% and none deviates by more than 10% 
 
 * Remaining tests to comply as per the finished product release 
specification. 
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7.10 Yield Statement: 
 
Sr. 
No. 
Stage Theoretical Yield 
1. Lubricated granules 46.802 kg 
2. After Compression 46.802 kg 
3. After Coating 48.000 kg 
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CHAPTER - 8 
1.0 RESULTS AND DISCUSSION 
2.0 8.1  Evaluation of physical parameters of Azithromycin:  
3.0 8.1.1  Organlopetic Properties: 
 Test Specification/Limits Observations 
Color 
White or almost white 
crystalline powder 
White crystalline 
powder 
Taste Bitter Bitter 
Odour Odourless Odourless 
 
8.2 Flow Properties (Angle of repose): 
Table No 11 
Material Angle of repose 
Azithromycin 32
o85” 
  
8.3 Determination of Densities: 
Table No 12 
Material Bulk Density (gm/ml) Tapped density (gm/Ml) 
Gliclazide 0.27 0.35 
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8.4 Powder compressibility:  
Table No 13 
 
Materials Compressibility index Hausner ratio 
Azithromycin 22.86% 1.30% 
4.0  
8.5 Solubility: 
It was determined as per procedure given in method section 5.1.6. The 
following table illustrated the result  
Table No 14 
Test  Specification  Result  
Solubility in water, 
alcohol.       
Practically insoluble in water 
Soluble in methanol, ethanol, 
chloroform, and 
dimethylchloride 
 
Complies 
 
Assay (by AZIT-IMTB-10-IN): 
Table No 15 
Test  Specification Observation  
Assay  99.0 - 101.0 99.89  
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8.6 Formulation Compositions: 
                                                      Table No 23 
INGRIDIENT              
NAME (mg) 
F1 F2 F3 F4 F5 F6 
Azithromycin 
dehydrate 
262.00 262.00 262.00 262.00 262.00 262.00 
Microcrystalline 
cellulose 
19.06 19.06 19.06 19.06 19.06 19.06 
Pregelatinized starch 12.00 12.00 12.00 12.00 12.00 12.00 
Croscarmellose sodium 2.90 2.90 2.90 2.90 2.90 2.90 
Croscarmellose sodium 5.80 5.80 5.80 5.80 5.80 5.80 
Colloidal Silicon 
dioxide 
4.80 4.80 4.80 4.80 4.80 4.80 
Magnesium Stearate 4.80 4.80 4.80 4.80 4.80 4.80 
Purified water QS QS QS QS QS QS 
Total weight  312.00 312.00 312.00 312.00 312.00 312.00 
Coating  
Hydroxyl Propyl 
Methyl Cellulose 
(6cps) 
6.05 6.05 6.05 6.05 6.05 6.05 
PEG -6000 0.85 0.85 0.85 0.85 0.85 0.85 
Talc 0.50 0.50 0.50 0.50 0.50 0.50 
Titanium dioxide 0.50 0.50 0.50 0.50 0.50 0.50 
Quinoline yellow 0.10 0.10 0.10 0.10 0.10 0.10 
Purified water Qs Qs Qs Qs Qs Qs 
Total weight  320.00 320.00 320.00 320.00 320.00 320.00 
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8.7 Physical Parameters and Drug Content: 
Table No 24  
 
The formulated tablets were then evaluated for various physical 
characteristics like weight variation, friability, hardness, disintegration time, 
drug content, thickness. The weight variation of tablet was uniform in all 
formulations and ranged from 312±0.52 to 313±0.49. Friability values were 
ranged from 0.35 to 0.42. The hardness of prepared tablets was ranged from 
110±20 to 113±0.20.disintegration time of tablet values ranged from 84±0.6 to 
87±6.3. Drug content of tablets ranged from 98.02 to 99.46 And the thickness 
values were ranged from 3.1±0.008 to 3.3±0.008.  
 
 
 
Formul- 
ations 
Weight 
variation 
(n=20) 
(mg ± SD) 
 
Friability 
(%) 
Hardness 
(Newton) 
Disintegration 
Time 
(seconds) 
Drug 
content 
(%) 
Thickness 
(mg ± 
SD) 
F1 312±0.54 0.36 112±20  85±0.7 99.24 
 
3.2±0.009 
F2 311±0.91 0.35 113±20 86±0.8 98.16 
 
3.2±0.008 
 
F3 312±0.63 0.41 110±20 85±0.6 98.74 
 
3.2±0.011 
F4 312±0.52 0.42 111±20 84±0.6 98.02 
 
3.1±0.010 
F5 313±0.49 0.36 112±20 86±0.7 98.21 
 
3.3±0.008 
F6 312±0.83 0.37 113±20 87±0.4 99.46 
 
3.2±0.008 
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8.8 Dissolution Data of Tablet Formulation of Azithromycin tablets: 
     Table No 25 
Time 
(min) 
 
CUMULATIVE PERCENT DRUG RELEASE (%) 
F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
15 45.19 49.13 41.05 50.04 46.15 46.72 
30 75.61 71.91 70.13 71.19 70.89 71.17 
45 91.09 96.94 93.61 99.92 93.22 97.61 
60 98.71 99.54 98.76 -- 99.07 -- 
 
 
Fig No 13: In-vitro Dissolution Graph of Tablet Formulation of 
Azithromycin tablets 
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Dissolution data of Optimized Formulation and Marketed Brand: 
8.9 Comparison with the Marketed Product 
Table No 26  
Time 
(min)  
Mean Cumulative % Drug 
Release  
F4  Marketed product  
0  0  0  
15  50.04  39.63  
30  71.19  68.25 
45  99.92  93.07  
60  -- 99.48  
 
 
                    Fig No 14: Comparision with the Marketed Product 
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8.10 STABILITY STUDIES: 
Optimized formulation (F4) was subjected to stability studies at 40
o
c± 
2
o
c/75% RH ±5 % for 2 months. The product was evaluated for appearance and 
hardness. Drug release studies were conducted as per the planned scheduled as 
above. 
Storage conditions at: 40
O
C2 OC/ 75 % RH5%.  
Stability studies are evaluated for following parameters 
 Hardness 
 Friability 
 Weight variation 
 Drug content 
 In-vitro dissolution studies 
Descriptions: 
Batch No – Demo batch                 Packing – Yellow PVC blister 
B. Size – 12000 tablet 
 
    Storage condition 
 
        40 °C, 75 % RH 
Sr. 
No 
Tests Specification Initial 1 month 2 month 
1 Description Yellow colored, round 
shaped, biconvex, 
coated tablet, plain on 
both side. 
complies Complies complies 
2 Assay (%) 90 % to 110 % of 
label claim 
99.7 99.2 100.1 
3 Water content (%) To record 5.12 5.32 5.40 
4 Disintegration 
time 
Not more than 30 
minutes 
1.56 1.30 2.45 
5 Dissolution at pH 
6.0 phosphate 
buffer 
Not less than 75 % (D) 
in 45 minutes 
95.2 
(0.58) 
99.4 9 
(0.85) 
100.6 
(2.08) 
Observation: Stability data show that drug product is stable upto 2 month in 
accelerated condition  
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Observation: Stability data show that drug product is stable upto 2 month in 
intermediate condition. 
 
 
 
 
 
 
 
 
 
 
 
Batch No – Demo batch                 Packing – Yellow PVC blister 
B. Size – 12000 tablet 
 
    Storage condition 
        30 °C,  75 % RH 
S.
No 
Tests Specification Initial 1 month 2 month 
1 Description Yellow colored, round 
shaped, biconvex, 
coated tablet, plain on 
both side. 
complies Complies complies 
2 Assay (%) 90 % to 110 % of 
label claim 
99.7 99.5 98.8 
3 Water 
content (%) 
To record 5.12 5.42 5.6 
4 Disintegratio
n time 
Not more than 30 
minutes 
1.56 2.00 2.00 
5 Dissolution 
at pH 6.0 
phosphate 
buffer 
Not less than 75 % 
(D) in 45 minutes 
95.2(0.58
) 
97.6 97.5 
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Batch No – Demo batch                Packing – Yellow PVC blister 
B. Size – 12000 tablet 
    Storage condition 
 
        25°C,  60 % RH 
S.
No 
Tests Specification Initial 1 month 2 month 
1 Description Yellow colored, round 
shaped, biconvex, 
coated tablet, plain on 
both side. 
complie
s 
Complie
s 
complies 
 
2 Assay (%) 90 % to 110 % of 
label claim 
99.7 99.9 100.0 
3 Water content 
(%) 
To record 5.12 5.28 5.30 
4 Disintegration 
time 
Not more than 30 
minutes 
1.56 2.00 2.10 
5 Dissolution at 
pH 6.0 
phosphate 
buffer 
Not less than 75 % 
(D) in 45 minutes 
95.2(0.5
8) 
96 97.23 
 
 
 
Observation: Stability data show that drug product is stable upto 2 month in 
normal condition  
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CHAPTER - 9 
                             CONCLUSION 
From the present work , it can be concluded that the results suggested 
that the prepared formulations were stable and globally acceptable. In the wake 
of patentability of immediate release dosage forms 
The results of the present research work gives idea about the formulation 
of various bacteriostatic drugs as immediate release dosage forms. The research 
work was done with economical, commercial and regulatory point of view. The 
final products developed in the research may be commercialized after the 
establishment of the safety and efficacy in the human volunteers. 
In future , with the help of invivo studies reduction is dose is possible, 
which reduce adverse effect 
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